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Abstract 
Herpes simplex viruses (HSVs), are among the most virulent and widespread pathogens; 
they affect 60–90% of the population worldwide. Substantial evidence indicates a 
possible association between pathogens and chronic disease. HSVs, among other viruses, 
have been associated with increased risk for inflammatory diseases. However, prior 
findings have been inconsistent on the role of infection in triggering autoimmune 
response and chronic disease. This study builds on the premise that pathogens can induce 
an inflammatory response and increase the risk for disease development. A representative 
U.S. sample from NHANES, a national population-based cross-sectional survey, was 
used to examine the relationship between HSVs infection and type 2 diabetes mellitus 
(T2DM) and cardiovascular disease (CVD). Results from the two-tailed, Pearson chi-
square test and multiple logistic regression analyses found no significant association 
between HSV or multiple herpes virus infections and T2DM or CVD, which suggest 
rather a secondary phenomenon. However, all the risk factors examined in this study 
indicated an association with either T2DM, CVD or both. Two inflammatory markers, C-
reactive protein (CRP) and serum ferritin, were significantly associated with T2DM and 
CVD. These findings have potential implications for social change as they support the 
premise that high levels of CRP and ferritin may be associated with T2DM and CVD. 
Existing guidelines for primary and secondary prevention of T2DM and CVD could be 
expanded (a) to include CRP and ferritin as part of the health assessment for T2DM and 
CVD in high-risk populations, and (b) to explore the effectiveness of CRP and ferritin as 
predictive biomarkers and prognostic tools for T2DM and CVD. 
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Chapter 1: Introduction to the Study  
Background 
The growing list of chronic diseases previously considered to have a 
noninfectious etiology is of great public health concern (SoRelle, 1998). Cancer, for 
example, one of the most studied chronic diseases, is also recognized as an inflammatory 
disease that has been linked to an infectious etiology (Schlipköter & Flahault, 2010; Zur 
Hausen, 2009). One of the mechanisms linked to the comorbidity of pathogens and 
inflammatory diseases is that infection must be chronically active (Sfriso et al., 2010). 
This pathogenic mechanism has been observed in infectious agents such as epstein-barr 
virus (EBV), Helicobacter pylori (H. pylori), and herpes simplex viruses (HSVs), which 
are able to elude immune recognition and HSVs can stay dormant and reactivate for the 
life of the host (Kusters, van Vliet, & Kuipers, 2006; Lima et al., 2008). Of significant 
note is the fact that infections may be cofactors that indirectly affect genetic mutations, 
while the direct pathway to disease development may be noninfectious (Christen, Hagen, 
Shigenaga, & Ames, 1999). This phenomenon can be explained by the fact that a 
substantial part of the inflammatory disease processes may result from an autoimmune 
response to chronic inflammation leading to the belief that the etiology of the disease is 
not related to infection (Christen et al., 1999; Sfriso et al., 2010). Considerable evidence 
has been accumulated in favor of chronic viral or bacterial infections with cardiovascular 
diseases, diabetes mellitus, atherosclerosis, and Alzheimer’s disease, among other 
chronic diseases (O’Connor, Taylor, & Hughes, 2006). 
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Introduction  
Researchers are beginning to understand the role that chronic inflammation may 
play in the pathogenesis of chronic diseases (Lutsey, Pankow, Bertoni, Szklo, & Folsom, 
2009). It has been documented that highly virulent agents may induce inflammation as a 
result of a robust immune response creating a susceptible environment conducive to 
disease development (Conrady, Drevets, & Carr, 2011; Lutsey et al., 2009; van der Kleij 
& Yazdanbakhsh, 2003). The biological plausibility of theories linking pathogen-induced 
inflammation and autoimmune-inflammatory disease has been examined in prior work 
(Watts, Crimmins, & Gatz, 2008). Although promising findings have been reported, most 
results have been inconsistent (Bauer & Meyer, 2011; Gómez, Laurés, Baltar, Melón, 
Dı́ez, & de Oña, 2005; Lutsey et al., 2009; Sethi et al., 2008; Sun et al., 2004).  
Over the years, the epidemiology of the highly pathogenic HSVs has changed 
dramatically. Eight out of the 80 known viruses in the herpes family to date are 
recognized as human pathogens (Fatahzadeh & Schwartz, 2007). In the United States, 
trends in genital herpes with HSV type 2 (HSV-2) showed a decrease of 21.0% (95% CI: 
19.1-23.1) from 1988-1994 to 17.0% (95% CI; 15.8-18.3) from 1999-2004 among 
individuals aged 14-49 years (CDC, 2010a, 2010b). Nevertheless, an increase among 
individuals diagnosed with genital herpes with herpes simplex virus type 1 (HSV-1) has 
been observed in later years, 1.8% in 1999-2004 versus 0.4% in 1988-1994 (P<.001) 
(Malkin, 2004; Xu et al., 2006; CDC, 2010a, 2010b). This new trend in genital herpes 
suggests a possible genetic crosstalk or immune-synergy between HSV-1 and HSV-2 
infections (Chentoufi et al., 2012; Kimberlin, 2004; Kriebs, 2008; Mark et al., 2008).  
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Worldwide, the prevalence of HSV is approximately 90% (Malkin, 2004; Smith 
& Robinson, 2002; Wald & Corey, 2007). In the United States, over 50% of the 
population is seropositive to HSV1 by the time they reach age 40 and approximately 25% 
is seropositive to HSV2 (CDC, 2010b; Kimberlin, 2004; Xu et al., 2006). This is of great 
public health concern given the evidence that people infected with HSV2 are up to three 
times more likely to acquire HIV and to transmit the HIV virus to others compared to 
people who are seronegative to HSV-2 and the new synergy trend observed between 
HSVs and HIV (Chentoufi, 2012; Freeman et al., 2006; Holmberg et al., 1988; 
McClelland et al., 2002; Schacker et al., 1998). According to the Centers for Disease 
Control and Prevention (CDC, 2006), transmission risks of HSV-2 are higher since over 
80% of those infected with the virus are asymptomatic, and the effectiveness of current 
prevention measures for HSV-1 and HSV-2 is limited to the use of condoms and 
prophylactic medications (Leone, 2005; Mell, 2008; Wald et al., 2001) and a potential 
vaccine still in development (Belshe, 2012; Samandary, 2014). Additionally, the cost of 
HSV-2 in the U.S. is expected to be nearly $2 billion by the end of 2015 (Szucs, Berger, 
Fisman, & Harbarth, 2001). To better understand disease risks and to develop effective 
treatments and prevention strategies, it is imperative to understand the epiphenomenon of 
infectious agents and their possible correlation with common chronic diseases. Findings 
from the present study inform the fields of medicine and public health about potential 
prevention measures for individuals at risk of CVD and/or T2DM, who are also 
seropositive to herpes virus infection. 
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Statement of the Problem  
HSVs are among the most virulent and widespread pathogens; they affect 60-90% 
of the population worldwide (CDC, 2010; Smith & Robinson, 2002; Wald & Corey, 
2007; Xu et al., 2006). Considering that HSVs have the ability to reactivate during the 
lifetime of the host, it is possible that the recurrent autoimmune and inflammatory 
response induced by these viruses may increase the risk for developing inflammatory 
chronic diseases, including two of the top 10 leading causes of death in the United States: 
T2DM and CVD (Lloyd-Jones et al., 2010; Lutsey et al., 2009). Most association studies 
conducted with pathogens and chronic diseases have used small samples of specific 
populations, including immunocompromised individuals, in clinical settings leading to 
conflicting results (Rupprecht et al., 2001; Sun et al., 2004). As a result, there is minimal 
understanding about the intricate relationship between infectious agents and chronic 
diseases. In this study, I further examined the relationship between human pathogenic 
HSVs and two chronic diseases, T2DM and CVD.  
Purpose of the Study  
This study sought to examine the potential relationship between HSV and two 
chronic diseases, T2DM and CVD in a U.S. representative sample, aged 20-49. Although 
inferences about causal factors cannot be made with cross-sectional studies, this study 
was expected to contribute to the existing literature by providing additional evidence on 
possible association between pathogens and chronic disease. I also examined if a higher 
burden of pathogens, such as having more than one type of herpes virus—for example, 
HSV-1, HSV-2, and cytomegalovirus (CMV)—increases the risk for developing T2DM 
5 
 
 
and/or CVD or if it is merely a secondary phenomenon. Further, I evaluated the 
relationship between three well-known inflammatory markers (CRP, serum ferritin, and 
homocysteine) and T2DM and CVD. Lastly, the prevalence of reported HSV infection, 
T2DM, CVD and selected inflammatory markers were examined to account for a true 
representative sample.  
Research Questions 
 The following hypotheses derived from the literature and steered the present 
study:  
H11: Is HSV-1 infection associated with higher risk of developing T2DM? 
H01: HSV-1 infection is not associated with higher risk for T2DM. 
H12: Is HSV-2 infection associated with higher risk for of developing T2DM? 
H02: HSV-2 infection is not associated with higher risk for T2DM. 
H13: Is HSV-1 infection associated with higher risk of developing CVD? 
H03: HSV-1 infection is not associated with higher risk for CVD. 
H14: Is HSV-2 infection associated with higher risk of developing CVD?  
H04: HSV-2 infection is not associated with higher risk for CVD. 
H15: Is having a higher burden of pathogens (HSV-1 + HSV-2+CMV) associated 
with a higher risk of developing T2DM and/or CVD? 
H05: A higher burden of pathogens is not associated with higher risk for T2DM 
and/or CVD. 
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The study methodology including study design, dependent and independent 
variables, covariates and potential confounders will be discussed in detail in Chapter 3, 
Methodology. 
Definition of Terms 
Acute-phase response (APR): The initial response or acute inflammation response 
of the innate immune system to injurious stimuli caused by harmful agents (Gruys, 
Toussaint, Niewold, & Koopmans, 2005). 
Autoimmune-inflammatory response: A mechanism induced by the innate immune 
system when tissues are injured by pathogens, trauma, toxins, extreme heat and cold, to 
name few. Damaged cells release chemicals that in turn cause cells to leak fluid to tissues 
causing swelling; hence inflammation (Firestein, 2011).  
Cardiovascular or heart disease (CVD): According to the World Health 
Organization (WHO), CVD refers to a variety of disorders of the heart, to include: 
Coronary heart disease (CHD), which is also known as coronary artery disease (CAD). 
CHD is caused by the build-up of plaque on the wall of the heart arteries blocking the 
blood and oxygen supply to the heart. Angina or chest pain is one of the most common 
risk factors for heart disease. Heart attack also known as myocardial infarction (MI) is 
caused by a blood clot, which in turn blocks the blood flow to the heart causing damage 
to the heart (Bonow RO, Mann, Zipes, & Libby, 2011; Greenland et al., 2012; WHO, 
2012).  
Type 2 diabetes mellitus: Characterized by an array of metabolic dysfunctions 
including insulin resistance and inadequate insulin and glucagon secretion. In this study, 
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the American Diabetes Association (ADA) criteria were utilized for the diagnosis of 
T2DM. According to Mahler and Adler (1999) “Impaired fasting glucose was defined as 
fasting plasma glucose of 110 or more and 125 mg/dl or less. Impaired glucose tolerance 
(IGT) was defined as a 2-h plasma glucose value of 140 or more and of less than 200 
mg/dl during an oral glucose tolerance” (p. 1165). Hemoglobin A1C measurements were 
applied to the diagnoses of diabetes (6.5% or greater) and (5.7%-6.4%) for prediabetes 
(ADA, 2003; Mahler & Adler, 1999).   
 Inflammatory markers: Also known as biomarkers are useful clinical diagnostic 
and prognostic tools for ruling out specific conditions. For example, elevated levels of C - 
reactive protein (CRP), a protein synthesized by the liver, are an indication of 
inflammation present in the body. As a result, CRP is used as a biomarker for the risk of 
CVD and T2DM. Interleukin or IL-6, a protein-coding gene, functions with inflammation 
in response to harmful stimuli such as infection. Fibrinogen, a protein synthesized by the 
liver, helps to stop clots from forming by converting thrombin into fibrin and may 
indicate a risk for diabetes. Elevated levels of ferritin, a protein that controls the levels of 
iron in the blood, may be an indication of inflammation, heart failure, diabetes and other 
conditions. Elevated levels of homocysteine, an amino acid found in the blood plasma, 
increase the risk for heart disease (Ballantyne & Nambi, 2005; Davidson, 2011; Ridker, 
Hennekens, Buring, & Rifai, 2000; Watson, Round, & Hamilton, 2012). 
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Significance of the Study 
Social Change Implications 
Results from this study are expected to add to the growing body of evidence that 
links infectious agents with chronic disease. A positive association between HSV and 
T2DM and CVD would provide the medical community and the public health field with 
valuable information that can be translated into clinical practice. Serologic testing for 
HSV could be included as part of a routine health assessment for patients at high risk for 
T2DM and CVD. Preventive screening could improve the health of susceptible groups, 
reduce health care cost, and foster policy change. Additionally, existing prevention 
guidelines for T2DM and CVD could be expanded to include inflammatory biomarkers—
including CRP, serum ferritin, and homocysteine—as predictive biomarkers for T2DM 
and CVD (Oshaug, Bugge, Bjonnes, Borch-Iohnsen, & Neslein, 1995; Braly, & Holford, 
2003; Laakso, 2008; Watson et al., 2012). This study could support more collaborative 
research across disease entities—such as T2DM, CVD and HSV—which are traditionally 
housed in separate silos for research and funding. 
Assumptions, Limitations and Strengths 
This study assumed that the survey participants were randomly selected and thus 
there was little or no selection bias. It is also assumed that the survey instrument used to 
collect the NHANES data was appropriate to measure the selected variables to test the 
research questions of this study. The clinical, physical, and self-reported data collected 
through NHANES annually provides a comprehensive health profile of each survey 
participant and allows for data validation. 
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The present study has a few limitations. First, it uses a cross-sectional design, 
which limits any causal inferences that can be made between associated variables. 
Second, it evaluates only a select number of inflammatory biomarkers based on those 
included in the NHANES dataset, rather than a more comprehensive list from a literature 
review. Third, it is not possible to determine whether the HSV infection included in the 
analysis is primary or recurring infection with the NHANES data. As a result, inferences 
cannot be made on truly primary infections versus recurring ones. This limitation also 
restricts the ability to determine whether any association exists between the chronicity of 
an HSV infection and the outcomes of interest, T2DM and CVD. Fourth, data to examine 
the interrelationship between inflammation, HSV and T2DM and/or CVD was not readily 
available. Fifth, a number of selected independent variables were collected through self-
report, which may result in an inaccurate or biased recall.  
This study also has several strengths. First, it uses a representative sample from a 
national population-based survey; hence, conclusions and implications drawn from this 
study can be applied to the general population. Second, the study uses serological 
measures for detecting antibodies for HSV-1 and HSV-2, as well as standard indicators 
for diabetes, CVD and inflammation markers, which allow for drawing conclusions from 
positive cases. Potential cofounders for T2DM and CVD seem unlikely given that most 
traditional factors (such as age, gender, smoking, and socioeconomic status) and 
nontraditional markers (such as C-reactive protein levels) were weighted and controlled 
for in the study population.  
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Summary  
  This is the first study to offer a closer look at the possible association of HSV and 
two leading chronic diseases, T2DM and CVD, using a nationally representative sample. 
The study design supports the examination of the cross-sectional relationship between 
seropositivity of HSV and these two inflammation-prone diseases. Although causal 
conclusions cannot be made with this cross-sectional study, findings and implications 
could provide the scientific community with additional evidence on whether a possible 
association between HSV and T2DM and/or CVD exists. This study is also the first to 
examine the association between three inflammatory biomarkers and T2DM and CVD, in 
addition to evaluate the burden of infection among individuals with T2DM or CVD. An 
overview of each of the independent and dependent variables, study methodology, 
discussion of study results, and recommendations are discussed in the next chapter.  
Chapter 2 begins with a review of the existing literature on the suggested 
association between infectious diseases and inflammatory response. The chapter includes 
a description of the pathogenic effect in autoimmune-inflammatory response theory, 
which serves as the theoretical framework for the current study and provides substance 
regarding the possible association of innate immunity, inflammation, and pathogen-
induced acute response. The chapter also discusses the possible mechanisms involved in 
the activation of innate immunity of T2DM and CVD. Further, the epidemiology, 
pathogenesis, and immunopathological aspects of herpes virus infection—as well as the 
role of inflammation in the pathogenesis of T2DM and CVD—are examined. The chapter 
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concludes with association studies between HSV and T2DM and/or CVD and research 
gaps.  
Chapter 3 describes the study’s methodology, including the analysis conducted to 
answer the research questions, including the use of regression analyses (chi-square, 
logistic, and stepwise) as a valid means to measure the possible relationship between 
HSV and T2DM and/or CVD. In addition, Chapter 3 includes a description of the study 
design, study population, variables to be studied, potential bias, and ethical 
considerations.  
Chapter 4 offers a summary of the analyses and the results. It describes the 
demographic and health characteristics of the study population as well as the distribution 
of the herpes viruses, biomarkers, diabetes and cardiovascular disease in the study 
sample. The prevalence of T2DM and CVD among individuals with HSV and selected 
covariates as well as the potential relationship between these are examined. Results are 
illustrated in tables and figures. 
Chapter 5 provides an overview of the findings, the conclusion, and the 
implications for social change. This chapter also evaluates potential reasons for study’s 
findings and existing evidence in support of them. Since a national representative sample 
was used in this study, association inferences would be appropriate. Limitations of the 
present study are also discussed.  
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Chapter 2: Literature Review 
Introduction 
 A comprehensive review of the literature relevant to this study was conducted. 
Two electronic databases were searched: Medline and PubMed. Google Scholar and 
references cited in key articles were also evaluated. Search terms were selected from the 
literature review from peer-reviewed journals dating back 1970: herpes (inflamed, 
inflammation or inflammatory) and (disease or diseases or illness), herpes or HSV and 
(cardiovascular disease or CHD or CVD) and (diabetes, type 2 diabetes mellitus, T2DM) 
and (inflammation or inflammatory) and (disease or diseases), herpes or HSV and (CHD 
or CVD) and (inflammation or inflammatory) and (disease or diseases), and T2DM and 
CVD inflammatory markers. Peer-reviewed articles and/or abstracts in English were 
retrieved. This chapter provides (a) an overview of the theoretical constructs; (b) the 
epiphenomena of the autoimmune-inflammatory response, HSV, CHD, and T2DM; (c) 
the possible interaction among these constructs; and (d) the different mechanisms that 
could account for an association.  
Theoretical Constructs 
This study builds on the premise that pathogens, particularly those that can 
reactivate during the lifetime of the host, can induce an autoimmune-inflammatory 
response. Chronic, inflammation-prone diseases may thereby increase (Conrady et al., 
2011; De Tiege, Rozenberg, & Heron, 2008; Itzhaki & Wozniak, 2008; McKie, Brown, 
MacLean, & Graham, 1998). Although there is a great deal of knowledge about the 
antigen-antibody (immune) mechanism produced by B and T lymphocytes and the 
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inflammatory cytokines, such as interferon- , interleukin-6 and chemokines (Figure 1), 
the pathogenic effect in autoimmune-inflammatory response is not well understood. 
Limited research has been conducted with human subjects and animal models to examine 
the interaction between infectious agents such as herpes viruses and the immune system 
and their effect on inflammation and potentially disease development, making it difficult 
to apply the theory to clinical medicine (Moynihan & Ader, 1996).  
 
Figure 1. Nature and functions of auto-antibodies (A-inflammatory cytokines and 
chemokines & B-antibody & antigen response). From “Nature and Functions of 
Autoantibodies,” by K. Elkon and P. Casali, 2008, Nature Clinical Practice 
Rheumatology, 4, p.12. doi: 10.1038/ncprheum0895 Adapted with permission of the 
author.  
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Innate Immunity, Inflammation, and Acute-Phase Response 
Research studies on one of the most studied human herpes virus, HSV type 5 
(HHV-5), also known as cytomegalovirus (CMV) indicate that this specific virus strand 
may be dependent on immune activation as it has been observed in tissues targeted by the 
immune system (Stevens, 1989; Steiner,1995). The ability of this virus to control 
immunological functions by activating T cells, a type of white blood cell that plays an 
important role in the immune system, and to produce cytokines for the virus to reactivate 
from its latent phase in macrophages suggests that it may play a causative role in the 
development of cancer, CVD, and autoimmune diseases (Soderberg-Naucler, 2006).  
Soderberg-Naucler (2006) illustrated how CMV may utilize inflammation as a 
mechanism to reactivate itself, then spread to other cells in the inflamed tissue, and 
through its ability to affect numerous cellular and immunological functions, activates the 
innate immunity causing disease (Figure 2). A similar mechanism was observed by 
Pickup (2004) in examining the role of inflammation and the activation of the immune 
system in the pathogenesis of T2DM. This epiphenomenon has been observed in 
inflammatory diseases such as multiple sclerosis, diabetes, and cancer (Pickup & Crook, 
1998; Soderberg-Naucler, 2006). Additionally, these diseases may provide a 
microenvironment that may in turn reactivate the virus triggering and sustaining 
inflammation (Soderberg-Naucler, 2006). While the innate immune system is the body's 
main defense against external threats such as infections, inflammation also functions as 
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the local protective response to tissue injury, which acute-phase reactant proteins such as 
CRP, cytokines IL-6, and TNf-alpha assist with limiting injury and healing tissue (Cone, 
2001; Gabay & Kushner, 1999; Muller et al., 2002). An increase in these and other acute-
phase responses induced by inflammatory cytokines when having fever or lethargy, have 
been observed in diabetes, atherosclerosis, arthritis and cancer patients (Pickup, 2004; 
Soderberg-Naucler, 2006).  
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Figure 2. Mechanism between inflammation, infection and immunological functions. 
From “Does Cytomegalovirus Play a Causative Role in the Development of Various 
Inflammatory Diseases and Cancer?” by C. Soderberg-Naucler, 2006, Journal of Internal 
Medicine, 259(3), p. 223. doi:10.1111/j.1365-2796.2006.01618.x. Adapted with 
permission from John Pick Up. Adapted with permission of the author. 
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Relationship Between Pathogens and Inflammatory Diseases 
 The association between human diseases and infectious agents has been widely 
documented. Alzheimer’s disease, for example, has been associated with various 
pathogens including HSV-1, Chlamydia pneumoniae, and Helicobacter pylori (Karim, 
2014; Kountouras et al., 2009; Shima, Kuhlenbaumer, & Rupp, 2010). HSV-1 has been 
linked to Alzheimer’s patients who have the APOE-4 form of APOE gene, which enables 
HSV-1 to enter into the brain cells (Itzhaki et al., 2008). Atherosclerosis, CHD and 
Asthma, particularly adult-onset asthma has been associated with Chlamydia pneumoniae 
and HSV-1, and the latter with rhinovirus (Gern, 2009; Hahn, Dodge, & Golubjatnikov, 
1991; Prager et al., 2002; Roivainen et al., 2000). Further, approximately 20% of all 
cancers have been linked to pathogenic agents (Pisani, Parkin, Munoz, & Ferlay, 1997). 
Human papillomaviruses (HPV) have been associated with several type of cancers, 
including anal and colorectal cancer, breast cancer, cervical cancer, lung cancer, and 
some skin carcinomas (Abramowitz et al., 2010; Bosch, Lorincz, Munoz, Meijer, & 
Shah, 2002; Burnett-Hartman, Newcomb, & Potter, 2008; Joh et al., 2010; Lawson, 
Gunzburg, & Whitaker, 2006).  
Similar to HSV-1, CMV or HHV-5, is often acquired during childhood, and 
affects the majority (over 70%) of the world’s population (Britt & Mach, 1996; Onorato, 
Morens, Martone, & Stansfield, 1985). As with most herpes viruses, CMV can spread 
through bodily fluids including saliva, breast milk, semen, blood and tissue transplants 
(Britt et al., 1996). Once acquired, CMV can persist and live as a latent infection in the 
host (Onorato et al., 1985). In a study conducted by Soderberg-Naucler and colleagues 
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(2006), a high prevalence of CMV was found in most of the HIV-infected patients who 
received organ or bone marrow transplants. CMV has also been associated with long-
term complications such as atherosclerosis, restenosis, transplant vascular sclerosis 
(TVS), rheumatoid arthritis, and systemic lupus erythematosus or SLE (Grattan et al., 
1989; Torok-Storb, Fries, Stachel, & Khaira, 1993; Zhou et al., 1996). CMV has also 
been associated with several cancers, dementia, lupus, metabolic syndrome, myocardial 
infarction, and lately it has been associated with T2DM (Barzilai et al., 2007; 
Dziurzynski et al., 2012; Gabrylewicz et al., 2003; Nabipour, Vahdat, Jafari, Pazoki, & 
Sanjdideh, 2006; Rider, Ollier, Lock, Brookes, & Pamphilon, 1997; Roberts & Cech, 
2005a). Moreover, CMV is one of the most common birth defect causing infections 
influencing mental retardation and hearing loss (Fowler et al., 1992; Onorato et al., 
1985). 
 Chen and colleagues (2012) examined the prevalence of CMV among older adults 
and showed that seropositive cases of CMV were also T2DM positive (17.2% vs 7.9%,   
(p = 0.016) with significant high levels of HbA1c (p = 0.014). These findings give basis 
to suggest that CMV and T2DM may be linked by the autoimmune inflammatory 
response, which may increase susceptibility to the virus or alternatively increase the risk 
of disease development (Jun & Yoon, 2003). This also may be an indication that 
inflammation may act as a mediator in disease development leading to believe that there 
is no link to pathogenic etiology when in fact there may be (Jun & Yoon, 2003; Lecube et 
al., 2004 Mehta et al., 2003; Roivainen et al., 2000; Zhu et al., 2001). The link between 
infectious diseases and T2DM, CVD, coronary artery disease (CAD) and atherosclerosis, 
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however, has been controversial given that the cause of most of these conditions are 
considered multifactorial (Jun et al., 2003; Luscher, Creager, Beckman, & Cosentino, 
2003; Zhu et al, 2001). Hypertension, obesity, smoking, hypercholesterolemia, and 
genetic predisposition are some of the common risk factors associated with most of these 
conditions (Fong, 2000; Ross, 1999). Obesity, for example, is known to play an important 
role in insulin resistance, diabetes and atherosclerosis (Fernandez-Real, Ferri, Vendrell, 
& Ricart, 2007; Karjala et al., 2011). Nevertheless, studies conducted with CAD patients 
showed no association with none of the traditional risk factors while their atherosclerosis 
appeared to have started in early childhood (Nieto, 1998; Ridker, 1999). These results 
support the premise that atherosclerosis may have a pathogenic etiology and chronic 
inflammation may be a precedent mechanism in the development of the disease. Further 
examination conducted by Fong (2000) showed epidemiological, pathological, and 
biological evidence supporting the association between CVD and infectious agents 
including Chlamydia pneumoniae, cytomegalovirus (CMV), HSV, and Helicobacter 
pylori (H. pylori). However, some of the association between CMV and CVD were found 
to be weak and in some studies controversial (Fong, 2000). The link between Chlamydia 
pneumonia (C. pneumonia) and CVD, however, seems to be well established 
(Ossewaarde, Feskens, De Vries, Vallinga, & Kromhout, 1998). The ability of infectious 
agents to induce inflammatory mechanisms and immune response has been widely 
demonstrated experimentally (Muhlestein, & Anderson, 2003).  
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Inflammation and Activation of Innate Immunity in Type 2 Diabetes 
There is a great deal of evidence that suggests inflammation is involved in the 
pathogenesis of T2DM (Navarro & Mora, 2005; Pickup & Crook, 1998; Schmidt et al., 
1999; Temelkova-Kurkschiev et al., 2002). Yet, the role of innate immunity and 
inflammation in the development of the disease is still uncertain (Saito et al., 2000; 
Schmidt et al., 1999; Snijder et al., 2003; Spranger et al., 2003). Given that the innate 
immune system is the body's main defense against external threats including infections, 
activation of innate immunity may explain some of the different clinical and biochemical 
conditions in T2DM patients (Fearon, 1997). These include obesity, hypertension, 
accelerated atherosclerosis, dyslipidemia, and limb ischemia. Inflammatory markers such 
CRP and interleukin-6 as well as traditional risk factors used to predict T2DM and CVD 
such as age, inactivity, nutrition, smoking, stress, and low-birth weight have also been 
identified as  innate immunity activators (Freeman et al., 2002; Pradhan, Manson, Rifai, 
Buring, & Ridker, 2001). Pradhan and colleagues (2001) prospective and nested case-
control study aimed to determine the role of inflammatory markers interleukin and CRP 
in the development of T2DM. One hundred eighty-eight women from a national sample 
of 27,628 healthy middle-aged women participated in the clinical study and were 
followed since 1992. Elevated levels of CRP and IL-6 were observed among those who 
developed diagnosed T2DM over a 4-year follow-up period. Baseline levels of IL-6 and 
CRP (P <.001) were significantly higher among women who developed T2DM than 
among those nondiagnosed. The relative risks for developing T2DM among women with 
high levels of these inflammatory markers were 7.5 for IL-6 (95% CI, 3.7-15.4) and 15.7 
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for CRP (95% CI, 6.5-37.9). Associations persisted after adjustment for traditional risk 
factors including fasting insulin levels, smoking, exercise, alcohol use, BMI, and family 
history of diabetes. A cross-sectional study conducted by Gregor & Hotamisligil (2011) 
with nondiabetic subjects and individuals with impaired glucose tolerance found a 
positive correlation between plasma insulin concentration, triglycerides, body mass index 
(BMI) and inflammation-induced acute-phase reactants. Elevated acute-phase markers 
have also been observed in clinical studies conducted with diabetic patients in 
comparison with nondiabetic subjects (Sriharan et al., 2002). Similar metabolic changes 
were reported by Richardson & Tayek (2002) in T2DM patients with systemic injury 
caused by trauma, infection, or cancer. These findings may imply that the injury response 
may be a factor in insulin resistance or increase in glucose production Temelkova-
Kurktschiev, Henkel, Koehler, Karrei, & Hanefeld, 2002). Similarly, cytokine-induced 
insulin resistance, may increase the acute-phase response increasing the risk for T2DM 
and CVD (Fernandez-Real & Ricart, 1999). Concentrations of CRP, fibrinogen, and 
plasminogen activator inhibitor-1 (PAI-1) were studied with 1,047 nondiabetic subjects 
enrolled in a longitudinal Insulin Resistance Atherosclerosis Study (Festa, D'Agostino, 
Tracy, & Haffner, 2002). Results from this study indicated significant increased levels of 
these inflammatory markers among T2DM cases than among no converters also known 
as controls (fibrinogen p = 0.013; CRP = 0.0001; PAI-1 p = 0.0001). PAI-1 was found to 
be an independent risk factor for T2DM.  
In his work, Pickup (2004), demonstrates the interaction between the different 
mechanisms and factors known to be activators of the innate immune system interacting 
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with cytokine production, which might leads to insulin resistance and other components 
of the metabolic syndrome (Figure 3). This mechanism is of particular interest since 
activated innate immunity might be a possible common antecedent of both T2DM and 
atherosclerosis (Pickup & Mattock, 2003). Another mechanism examined by Pickup 
(2004) is the fetal and neonatal programming, which suggests that prolonged 
environmental stressors may cause genetic mutations which may alter normal 
physiological responses to stress and other environmental exposures causing disease in 
individuals with a higher propensity to a hyper-responsive innate immune system. This 
theory is supported by the premise that low birth weight has been linked to high levels of 
acute-phase reactants in adults (Barker, 1995); therefore, it is assumed that acute-phase 
reactants may be precursors to certain types of autoimmune-inflammatory disease 
(Phillips et al., 2000).  
 Genetics and race have also been examined as possible mechanisms in the 
development of T2DM. In a study conducted by Pannacciulli and colleagues (2002), 
higher levels of CRP were recorded in women with family history of T2DM compared to 
those without a family history. When looking at the effects of race in the acute-phase 
response, higher concentrations of serum sialic acid have been reported in Asian diabetic 
patients with Indian descendant compare to White diabetic subjects (Pickup, Chana, 
Mattock, Samuel, & Mather, 1996). Another mechanism considered to influence the 
development of T2DM is individual diet, which may contribute to the activation of the 
innate immune system and chronic inflammation. Bakker et al. (2010) study 
demonstrates that excess and repeated dietary intake of certain high fatty foods may 
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affect the production of proinflammatory cytokines. In fact, prior studies conducted with 
diabetic subjects have shown a relationship between elevated levels of CRP and acute-
phase reactants (TNF-alpha and IL-6) and obesity (Vlassara et al., 2002).  
 Further, several studies have linked a number of inflammatory makers with 
specific ethnic groups and gender. In a study conducted with a middle-aged population 
diagnosed with T2DM, Schmidt et al. (1999) found a series of markers including white 
blood cell count, low serum albumin, fibrinogen, alpha 1-acid glycoprotein, and sialic 
acid, which have also been used to predict CVD (Kannel, Wolf, Castelli, D’Agostino, 
1987; Meade, 1997; Wannamethee et al., 2002; Yarnell et al., 1991). CRP has been 
observed predominantly in the older Scottish (Freeman et al., 2002) and Japanese 
population (Nakanishi, Yoshida, Matsuo, Suzuki, & Tatara, 2002) and German men 
(Spranger et al., 2003; Thorand et al., 2003). Both, CRP and IL-6, have been found 
mainly in women (Pradhan, Manson, Rifai, Buring, Ridker, 2001; Snijder et al., 2003) 
whereas white blood cell count have been observed in Pima Indians (Vozarova et al., 
2002). CRP, fibrinogen, and plasminogen activator inhibitor-1 (PAI-1) have been 
associated with multiethnic subjects with insulin resistance and atherosclerosis (Barzilay 
et al., 2001; Duncan et al., 2000; Festa, D'Agostino, Tracy, & Haffner, 2002).  
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Figure 3. Activators of the innate immune system, insulin resistance, T2DM and 
atherosclerosis. From “Inflammation and Activated Innate Immunity in the Pathogenesis 
of Type 2 Diabetes” by J.C. Pickup, 2004, Diabetes Care, 27(3), p. 816. 
doi:10.2337/diacare.27.3.81. Adapted with permission of the author. 
 
 
Inflammation and Activation of Innate Immunity in Cardiovascular Disease 
 Inflammation has also been associated with the pathogenesis of atherosclerosis 
(Blake & Ridker, 2002; Galkina & Klaus, 2009). Inflammatory markers previously 
associated with T2DM including CRP, fibrinogen, TNF sialic acid, and cytokines have 
also been found to increase the risk for myocardial infarction, stroke, peripheral vascular 
disease, and CVD mortality (Libby, Ridker, & Maseri, 2002; Ridker, 1999). Most risk 
factors such as hyperglycemia, dyslipidemia, and alterations in inflammatory mediators 
closely related to insulin resistance have also been observed in patients with CVD 
(Erdmann, 2005). Furthermore, it has been documented that serum sialic acid predicts 
cardiovascular mortality in T2DM patients independently of atherosclerosis 
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predisposition (Pickup et al., 1995). This findings suggests that innate immune response 
is a common precedent in atherosclerosis and diabetes. Thus, the acute-phase responses 
inherent to T2DM may promote the acceleration of atherosclerosis in diabetic patients 
(Pickup & Mattock, 2003). However, inflammatory markers have been observed in 
diabetic subjects without atherosclerosis and other vascular complications (Schmidt et al., 
1999). Yet, other manifestations and complications of T2DM including the presence of 
infectious agents, might further enhance inflammatory response (Crook, Tutt, Simpson & 
Pickup, 1993). Additional evidence indicates that diabetic patients with high incidence of 
atherosclerosis suffer from impaired immune response to pathogens leading to a greater 
risk for infection (Heymann et al., 2008). Epstain and colleagues (1999) studied patients 
who were seropositive to CMV and found an odd ratio of 1.3 (p = 0.7) and elevated CRP 
levels (odds ratio 2.3, p = 0.2) indicating a higher prevalence of CAD in patients who had 
combined CMV and elevated CRP levels (odds ratio 4.3, p = 0.01). Findings also showed 
a relation between infection, inflammation and CAD influenced by gender. In men, prior 
CMV infection was not associated with CAD, but rather with high levels of CRP. In 
women, the opposite effect was observed. Prior CMV infection was found to be 
independently predictive of CAD (Epstein, 2002).  
The relation between chronic inflammation and pathogen burden in relationship to 
chronic diseases has also been examined. Lutsey and colleagues (2009) used a random 
sample of 1,000 subjects, ages 45-84, from the Multi-Ethic Study of Atherosclerosis 
(MESA) to determine the cross-sectional relationship of five pathogens including 
C.pneumoniae, CMV, H. pylori, hepatitis A and HSV and T2DM. Results from this study 
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showed a higher prevalence of diabetes among subjects with a pathogen burden greater 
than three. No association was observed between individual infection agents and diabetes 
status suggesting no etiology role of infectious pathogens and the development of 
diabetes. However; a similar study was conducted with MESA to examine the association 
of cardiovascular pathogen burden and immune response in relation to socioeconomic 
and psychosocial gradients. Although the role of infection in CVD, particularly in 
atherosclerosis remains elusive, this study showed increased rates of CVD among 
subjects with a higher pathogen burden and low socioeconomic levels and chronic stress 
(Aiello et al., 2009). These findings suggest that a high burden rather than a single 
pathogen may be associated with increased risk of infection-related inflammation and 
cardiovascular damage (Zhu et al., 1999; Zhu et al., 2001). Further, stress has been linked 
to virus reactivation, which in turn flare up inflammation causing a dysfunctional 
immune response and leading to cardiovascular disease (Binkley et al., 2013).  
A literature review examining the pathogenic mechanisms between psoriasis and 
CVD, particularly atherosclerosis, indicated that both diseases fused into inflammation 
(Ghazizadeh, Shimizu, Tosa, & Ghazizadeh, 2010). When inflammation is induced, T-
cells are activated, chemokine and cytokine cells are produced resulting in the formation 
of psoriatic or atherosclerotic plaque. Similarly, a cross-sectional study conducted by the 
Netherlands Institute for Health Sciences Research compared patients with inflammatory 
arthritis (n = 1,518), patients with T2DM (n = 11,959), patients with osteoarthritis 
(n=4,040) and controls (n = 158,439) to determine if there was an association between an 
increased CVD burden on patients with selected inflammatory diseases. Study findings 
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showed a significantly moderate to high prevalence of CVD in arthritis cases OR = 1.5 
[1.2-1.9]) and T2DM cases OR = 1.3 [1.2-1.4] (Nielen et al., 2012). These findings 
demonstrate that these conditions share common underlying mechanism, which also lead 
to the assumption that inflammation might increase the risk for developing common 
chronic inflammatory diseases.  
Epidemiology of Herpes Viruses 
 Herpes simplex virus infections are prevalent worldwide (Malkin, 2004; Smith & 
Robinson, 2002). HSV-1 is more common than HSV-2 (Bradley, Markowitz, Gibson, 
McQuillan, 2014; Lafferty, 2002; Looker, Garnett, & Schmid, 2008). HSV-1 is acquired 
in early childhood with prevalence rates up to 40% by five years of age and by adulthood, 
HSV-1 affects over 60% of the population in the U.S. (Chayavichitsilp, Buckwalter, 
Krakowski, & Friedlander, 2009; Kimberlin,2014: Liesegang, 2001; Xu et al., 2006). 
Seroprevalence are similar worldwide; however, rates vary by country (kimberlin, 2014; 
Malkin, 2004; Smith & Robinson, 2002). However, in the United States, about one in six 
Americans (16.2 %) between the ages of 14 and 49 are infected with HSV-2. HSV-2 
seroprevalence estimates are almost two times higher among women (20.9%) than in men 
(11.5%); over three times higher among blacks (39.2%) than in whites (12.3%); with 
African American women disproportionately affected (48%)  (CDC, 2010b; Fanfair et al., 
2013; Johnson et al., 1989). In 2003, over 500 million people worldwide were estimated 
to be infected with HSV-2, with the lowest prevalence rates in Europe and highest in 
Africa (Looker et al., 2008).  
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Pathogenesis of Herpes Viruses 
 Herpes viruses are among the top leading cause of viral disease in humans of 
public health significance (Todar, 2009). These viruses have the ability to cause acute 
disease or remain latent, and reactivate over and over during the lifetime of the host 
(Roizman, Knipe, & Whiteley, 2007). HSV-1 and HSV-2 are responsible for causing 
infections in the orofacial region, central nervous system, and the anogenital region 
(Taylor, Brockman, McNamee, & Knipe, 2002). HVS-1 is spread through saliva of an 
infected person, mainly through common cold sores and blisters, while HSV-2 is spread 
mostly through sexual contact (Sacks et al., 2004; Taylor, Brockman, McNamee, & 
Knipe, 2002). Both HSV species are ubiquitous and highly contagious regardless of 
symptomology (Kesson, 2001).  
 The biology of herpes viruses is described by Holmes (1999) in his book, (3rd ed) 
Sexually Transmitted Diseases. These viruses belong to the family of DNA enveloped 
viruses known as Herpesviridae. Holmes (1999) explains that humans are natural 
reservoirs for HSV, which could cause mild to severe conditions in humans including 
encephalitis and meningitis. Conversely, the viral membrane of these viruses is sensitive 
to an array of chemicals and substances and would not survive in harmful environmental 
conditions (Hunt, 2010). In fact, a cell with a damaged lipid envelop is not be infectious 
and transmission from cell to cell is necessary for the virus to survive (Hunt, 2010). 
Nevertheless, these viruses have the ability to bind to the cell surface; fuse into the cell 
membrane and the inner nucleus where DNA replication occurs; encode viral proteins 
and synthesize viral DNA genome to replicate itself (Mingo, Han, Newcomb, & Brown, 
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2012; Shimomura, 2008). If the virus cannot synthesize viral proteins and enzymes in 
host cells or the host cells do not allow such replication due to the cell’s own 
composition, the virus would not be able to replicate (Mingo et al., 2012). Yet, herpes 
viruses are ubiquitous opportunistic pathogens. They have the ability to infect 
lymphocytes or epithelial mucosal cells; travel to and stay latent in nucleated neuron; and 
continue to reactivate at the same site of the initial infection (Mingo et al., 2012). 
Latency, which means that the virus remains dormant in the nerve cells, also plays 
an important role in the survival of HSV and host immune suppression (Steiner, 1995). 
Most adults carry HSV in its latent’s phase (Steiner, 1995). Once the virus cells are 
present in the body, antibodies are released, and T cells and macrophages are activated to 
kill infected cells (Khanna, Bonneau, Kinchington, & Hendricks, 2003). Given that HSV 
can infect almost any human cell, cell-mediated immunity for suppressing the infection is 
of great importance (Khanna et al., 2003). This immune response is normally followed by 
an inflammatory response that leads to some disease symptoms (Huang, Xie, Xu, Li, & 
Zao, 2011). Other known factors that might trigger a recurrence of the viral infection and 
may contribute to disease symptoms include stress, exposure to sunlight, heat, among 
others (Huang et al., 2011). 
  On rare occasions, herpes infections can result in serious sequelae and even life-
threatening complications including meningitis and encephalitis and other opportunistic 
infections such as keratitis and gingivostomatitis, particularly in neonates (Stanberry et 
al., 2000; Stanberry, & Rosenthal, 2002). Recent findings also suggest that HSV may 
increase the risk for diseases such as HIV/AIDS, cervical cancer, cardiovascular disease, 
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and metabolic syndrome (de Martel & Franceschi, 2009; Nabipour et al, 2006; Roivainen 
et al., 2000; Zhu et al., 2009). As described by Hunt (2010), Sandri-Goldin (2006), and 
Whitley (1996), there are eight herpes viruses known to be pathogenic to humans (Table 
1). These include Herpes simplex virus 1 (HSV-1), Herpes simplex virus 2 (HSV-2), 
Varicella zoster virus (VZV) or HHV-3, Epstein-Barr virus (EBV) or HHV-4, 
Cytomegalovirus (CMV) or HHV-5, Roseolovirus also known as Herpes Lymphoytopic 
virus or HHV-6, Roseolovirus or HHV-7, and Kaposi’s Sarcoma-associated herpes virus 
or HHV-8.  
Table 1 
Herpes Viruses Known to be Pathogenic to Humans 
Virus Common Name Subfamily 
Human herpes virus 1 Herpes Simplex type 1 alpha 
Human herpes virus 2 Herpes Simplex type 2 alpha 
Human herpes virus 3 Varicella zoster alpha 
Human herpes virus 4 Epstein-Barr gamma 
Human herpes virus 5 Cytomegalovirus beta 
Human herpes virus 6/7 Exanthum subitum roseola infantum beta 
Human herpes virus 8 Kaposi’s Sarcoma gamma 
 
Similar to HSV-1 and HSV-2, VZV or HHV-3 virus targets primary 
mucoepithelial cells, stay dormant for the life of the host in the neuron cells, and spread 
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through close and sexual contact with an infected person (Table 2). VZV is responsible 
for causing chickenpox and shingles and is considered airborne. HHV-4 targets B cells 
and epithelial cells, remains latent in B cells, and is spread through close contact, 
transplants and transfusions as well as vertical transmission (from mother to infant). 
Pathogenesis of this virus includes mononucleosis, Burkitt’s lymphoma and other 
lymphoma-like clinical symptoms associated with persons living with AIDS. HHV-5 
targets and stays dormant in monocyte, lymphocyte, and epithelial cells. It manifests as a 
mononucleosis-like syndrome and spreads through contact with saliva. HHV-6 and 
HHV-7 target and stay dormant primary in T cells. It has been suggested that these 
viruses may spread through close contact and air. Both viruses cause roseola infantum 
which is also known as the sixth disease that causes rashes in infants and young kids. 
HHV-8 targets primary lymphocyte cells and stays dormant in B cells. This type of virus 
causes Kaposi’s sarcoma and Multicentric Castleman’s Disease. The virus spreads 
through close and sexual contact with the infected person (Hunt, 2010; Sandri-Goldin, 
2006; Whitley, 1996).  
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Table 2 
Properties of Herpes Viruses  
Human 
Herpes 
Type 
Name Subfamily Target cell type Latency Transmission 
1 Herpes simplex-
1 (HSV-1) 
Alphaherpes-
virinae 
Mucoepithelia Neuron Close contact 
2 Herpes simplex-
2 (HSV-2) 
Alphaherpes-
virinae 
Mucoepithelia Neuron Close contact 
usually sexual 
3 Varicella Zoster 
virus (VSV) 
Alphaherpes-
virinae 
Mucoepithelia Neuron Contact or 
respiratory 
route 
 
4 Epstein-Barr 
Virus (EBV) 
Gammaherpes-
virinae 
B lymphocyte, 
epithelia 
 
B lymphocytes Saliva 
5 Cytomegalovirus 
(CMV) 
Betaherpes-
virinae 
Epithelia, 
monocytes, 
lymphocytes 
Monocytes, 
lymphocytes and 
possibly others 
Contact, blood 
transfusions, 
transplants, 
congenital 
 
6 Herpes 
lymphotropic 
virus 
Betaherpes-
virinae 
T lymphocytes 
and others 
T lymphocytes 
and others 
respiratory 
route 
 
7 Human herpes 
virus-7 (HHV-7) 
Betaherpes-
virinae 
T lymphocytes 
and others 
T lymphocytes   
and others    
 
 
Unknown 
8 Human herpes 
virus-8 (HHV-8)  
 
Gammaherpes-
virinae 
Endothelial cells Unknown Exchange of 
body fluids 
Note. Types of Herpes Viruses. From “Microbiology and Immunology Online,” by Hunt 
R. Retrieved 06/01/2013 from http://www.microbiologybook.org/virol/herpes.htmhtm 
University of South Carolina School of Medicine, Virology, Chapter 11 Herpes Viruses.   
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Immunopathological Aspects of HSV Infection 
 The human immune system responds by activating its natural defense system to 
remove detected foreign agents in the body. This defense mechanism against possible 
antigens may induce disease-like symptoms such as fever and inflamed glands while 
minimizing damage to the host (Banerjee & Rouse, 2007). However, immunopathology 
may occur when the host tissue is damaged by chronic immune reaction (Whitley, 
Kimberlin, & Prober, 2007). Recurrent lesions of HSV-2 in individuals with 
immunocompromised immune system are an example of a chronic immune response that 
can in fact increase the risk for other opportunistic conditions (Whitley et al., 2007). In 
fact, HSV and other herpes viruses such as HHV-6 have been identified as inflammatory-
causing lesion agents and the latter with possibly increasing the risk for multiple sclerosis 
(Koelle & Corey, 2003; Swanborg, Whittum-Hudson, & Hudson, 2003). Prolonged and 
chronic inflammatory reactions can cause damage to certain tissue sites or organs. For 
example, HSV infections may cause impaired vision, retinitis, and ganglionitis and have 
been associated with diseases like arthritis and Alzheimer’s disease (Pepose, 1991a, 
1991b; Stuart, Summers, Morris, Morrison, & Leib, 2004). The immune response to 
HSV-1 involves several mechanisms including the secretion of cytokines such as NK 
cells, CD4+ and CD8+ lymphocytes, TNF- a, IFN-a, and  IFN-y, which uphold antiviral 
action (Kumel et al., 1982; Linnavuori & Hovi, 1987; Weidinger et al., 2000). The ability 
of HSV-1 to interfere with the expression of major histocompatibility (MHC) class II 
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antigen during its active state and the MHC class I gene during its latent state is what 
allows the virus to evade the immune response; a phenomenon observed in HIV  
(Halford, Balliet, & Gebhardt, 2004; Sawtell, Thompson, & Haas, 2006). 
Association Studies Between Herpes Simplex Viruses and Diabetes 
 Although limited, the association between T2DM and CVD-prone pathogens have 
been examined in prior studies (Roivainen et al., 2000; Zhu et al., 2001). Yuhua (2005) 
and associates studied the relationship between HSV-1 and T2DM among 1,566 diabetic 
and nondiabetic subjects. Results indicated a significant association between HSV-1 and 
T2DM. Given that chronic inflammation is involved in the pathogenesis of T2DM, it is 
assumed that inflammation is flare up by an infectious agent such as HSV-1 (Pickup, 
2004). A recent study was conducted by Oke & Oke (2014) to investigate the prevalence 
of HSV-1 and HSV-2 in diabetic and nondiabetic patients in a diabetic clinic in Nigeria. 
The study population consisted of 320 patients aged 35-50. The prevalence of 
hyperglycemia in this study was approximately 85% with fasting blood sugar (FBS) 
ranging from 125 to 560 mg/dl. Approximately 50 (16%) had a normal glycemic reading 
ranging from 55-90 mg/dl. Among the 270 diabetic patients, 55 (20.4%) were diagnosed 
with ketonuria (as a result of insufficient insulin) and were seropositive to both, HSV-1 
and 2. Diabetic patients with no ketonuria were also seronegative for HSV-1 and HSV-2. 
This study shows a significant association between HSV-1 and 2 seropositivity and 
diabetes; particularly among diabetic patients with hyperglycemia and ketonuria. Ketosis-
prone T2DM is one of the most common forms of diabetes in African populations since 
1987, which researchers believe its onset is trigger by viral infection (Sobngwi et al., 
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2008; Tesfaye, Cullen, Wilson, & Woolley, 1991; Jun et al., 2003). These claims were 
also supported by Tesfaye and associates (1991) who reported cases of diabetic 
ketoacidosis induced by genital herpes. Similar results were reported by Sobngwi and 
colleagues (2008) who conducted a study to determine if an association between ketosis-
prone T2DM and other herpes viruses exists. A study population consisting of 187 (81 
ketosis-prone T2DM and 106 nonketosis T2DM) black patients of African origin were 
compared to 90 nondiabetic control group. A high prevalence of ketosis-prone T2DM 
and a very high prevalence (almost 6-fold higher) of HHV-8 infection among patients 
with ketosis-prone T2DM (approx. 87.7%) was observed compared to a lower prevalence 
of HHV-8 among nonketosis T2DM (15.1%) OR 39.9 [95% CI: 17.1-93.4] (P < .001) 
and among the control group (40%) OR 10.7[95% CI: 4.9-23.4] (P < .001).  
 The association between herpes virus entry mediator (HVEM), a receptor for 
HSV and cytokines, was studied in 840 obese individuals by Bassols et al. (2009). 
HVEM gene expression was found significantly higher in obese than in nonobese 
individuals (p < 0.0001). These results indicate a positive relationship between HVEM 
and obesity suggesting that this receptor may be a causal factor in the pathogenesis of 
obesity and inflammatory response (Bassols, Moreno, Ortega, Ricart, & Fernandez-Real, 
2009). Additional evidence supporting these findings was documented in a retrospective 
cohort study conducted by Shah and Hux (2003) to determine the risk of diabetic patients 
to acquire an infectious disease. Researchers looked at diabetic and nondiabetic patients 
in Ontario Canada at two points in time 1996 and 1999. The risk for acquiring an 
infection among diabetic versus nondiabetic patients was OR 1.21 [99% CI 1.20-1.11] 
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while attributable death among diabetic patients was up to OR 1.92 [CI 1.79 - 2.05]. 
These results provide additional evidence on possible increased susceptibility among 
immune compromised individuals to infection.  
Findings from a case-control study conducted by Roberts & Cech (2005b) 
indicated that a person previously exposed to one of the most common herpes viruses, 
CMV, has up to a 12 times greater chance of developing T2DM. Results also showed that 
diabetic patients had a greater seroprevalence of IgG CMV antibodies (97.6%) compared 
to nondiabetic patients (86.7%) with a statistical significance OR = 6.2 [95% CI: 1.1 – 
36.0] (p < 0.05). Greater odds were observed in a subset of patients with diabetes who 
had significantly more vascular complications than the controls OR = 12.4 [95% CI: 1.3 
to 117] (p < 0.05). A linear trend between diabetes, seropositivity to CMV, and age was 
also observed in this study. Given the association of atherosclerosis with diabetes and 
CMV, these findings support the premise that CMV may be a common factor between 
diabetes and CVD.  
Association Studies between Herpes Simplex Viruses and Cardiovascular Disease 
 
To examine the relationship between herpes simplex viruses and CVD, Mendy 
and colleagues (2013) conducted a cross-sectional study with 14,415 participants of 
NHANES 1999-2010, aged 20-49 years with a mean age of 34.3 years. Among the 
participants, over half (51.3%) were seropositive for HSV-1, 7.5% were seropositive for 
HSV-2 and 15.2% were seropositive to both HSVs. Results of this study indicated a 
significant association of HSV-2 with CVD OR 1.56 [95% CI = 1.09-2.21]; however, 
HSV-1 was not associated with CVD in this study OR 1.13 [95% CI = 0.79-1.62]. Yet, 
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HSV-1 and HSV-2 have been found in human atherosclerotic plaque (Gyorkey, Melnick 
Guinn, Gyorkey, & DeBakey, 1984; Friedman, Macarak, MacGregor, Wolfe, & 
Kefalides, 1981; Nicholson, & Hajjar, 1998). Likewise, CMV, a well-studied marker for 
atherosclerosis has been linked to endothelial dysfunction (Danesh, Collins, & Peto, 
1997).  
A prospective study conducted with 643 men to examine the association between 
HSV and CMV and MI and stroke indicated no evidence of these two pathogens 
increasing the risk for atherothrombotic. However, it has been suggested that perhaps 
viral particles may play a role in the initial process, but not at the clinical phase of the 
disease (Ridker, 1998, 1999). A population-based study with a similar sample size (515) 
examined the role of HSV-1 and CMV in CHD patients (Sorlie et al., 2000). A significant 
association between CMV and CHD with a higher risk in diabetic patients was reported 
in this study. However, no association was found between HSV and CHD suggesting 
some degree of disease-pathogen specificity (Sorlie et al., 2000). Nevertheless, while 
most studies conducted with CVD patients have focused on a single pathogen, it has been 
suggested that aggregate pathogen load may be associated with increased risk for CAD 
(Fernandez-Real et al., 2007). Pathogen burden has also been associated with plaque 
rupture and acute thrombotic occlusion, major risk factors for acute MI, as well as insulin 
resistance, a well-known factor for CAD (Epstein, 2002; Fernandez-Real et al., 2007). 
This premise has been extended by several prospective studies in which pathogen burden 
was found to be predictive of CVD (Zhu et al., 2001). Zhu and associates conducted a 
study with 124 middle-aged men to examine the effect of four pathogens: HSV, 
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enteroviruses, CMV, and chlamydia pneumonia, as well as insulin resistance. A strong 
association was observed in insulin resistance patients and seropositivity with multiple 
pathogens though a weak association was observed with a single pathogen including 
HSV. It should be noted that the small number of individuals who were seropositive for 
HSV-1 and HSV-2 may have limited the study’s ability to find a significant association 
with these two infectious pathogens.  
 In a cohort study of 890 patients who had CAD based on angiography, however, 
IgG antibodies for CMV, HSV-1, HSV-2, Hepatitis A virus (HAV) and CRP levels were 
found significantly higher in patients who subsequently developed MI (Zhu et al., 2009). 
 A similar study with contradictory results was conducted with 122 post-
menopausal women who tested positive for prior exposure to multiple infectious agents 
including C. pneumoniae, H. pylori, HSV, and CMV (Nabipour et al., 2006). Although 
results showed little evidence of the association between baseline serology of studied 
pathogens and risk for CVD, C. Pneumoniae has been implicated in chronic 
inflammatory response leading to atherosclerotic lesion progression in other studies 
(Altman, 2003; Campbell & Kuo, 2004; Grayston, Kuo, Campbell & Benditt, 1993; Wu 
& Wu, 2006). Equally, the longitudinal Helsinki Heart Study, a coronary prevention trial 
that monitor patients who suffered from myocardial infarction (MI) or coronary death 
during the eight and a half year trial period, examined CRP levels and antibodies for 
several viruses including HSV. Results from this study found higher levels of HSV-1 and 
Chlamydia pneumoniae antibodies in studied cases. The CRP mean was higher in cases 
in comparison to controls (4.4 versus2.0 mg/L: p < 0.001). The odds ratio for cases with 
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high antibodies and CRP levels were 2.4 [95% CI 2.9-3.3] for HSV-1 and 5.4 [95% 
CI2.4-12.4] for Chlamydia pneumoniae. The relative risk for high levels of antibodies for 
HSV-1 was 2.05 (95% CI 1.15-3.67) in nonsmokers and 23.74 for smokers [CI1.58-
8.86]. These findings demonstrate that high levels of antibodies of HSV-1 may be a 
marker for active, recurrent infection and a potential trigger for inflammation reaction 
increasing the risk for coronary heart disease (Benditt, Barrett, & McDougall, 1983; 
Gyorkey et al., 1984; Hoffmeister et al., 2001; Ridker et al., 1998; Roivainen et al., 
2000).  
 A few seroepidemiological studies have also linked HSV-2 as a potential 
cardiovascular pathogen; particularly, it has been implicated in atherosclerosis, CAD, and 
MI (Espinola-Klein et al., 2002; Nicholson et al, 1998; Rupprecht et al., 2001). HSV-2, 
however, have been associated with carotid wall thickening, vascular disease, 
thrombogenic and atherogenic of host cells (Sorlie et al., 1994). These findings have been 
extended by recent prospective studies specific to HSV-2. Sun et al (2004) investigated 
the relationship between HSV-2 and hypertension by inducing inflammation, a co-factor 
of HSV, in a cross-sectional study of 1,244 patients. The prevalence of HSV-2 IgG 
seropositivity was significantly higher in subjects with hypertension than in the control 
group (38.3% vs 29.8%, p = 0.002) and found to be an independent risk factor for 
hypertension (Sun et al., 2004). Similar results were found in a study of 31 patients 
undergoing coronary artery bypass. An association between inflammatory cells, cold 
sores, and HSV-2 antigen was observed in biopsies (Sun et al., 2004).  
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Summary  
 This literature review explored research in some areas of chronic diseases, 
autoimmune inflammatory response and infectious agents including those tested in the 
present study, HSV-1, HSV-2, and CMV. Current evidence demonstrates that 
inflammation is a co-factor of both, chronic disease and infection. Although the role of 
pathogens in the development of chronic disease is not well understood, studies that 
examined the underlying autoimmune responses of infection suggest an increased risk for 
developing inflammatory diseases. Alternatively, persons with chronic diseases may 
develop susceptibility to infection. Despite the accumulating evidence that infectious 
agents may predispose individuals to the development of chronic diseases, 
seroepidemiological studies continue to fail in demonstrating a strong causality or 
association between a single or multiple pathogens and disease development. Recent 
studies have hypothesized that if infection causes T2DM or CVD, it is likely to be caused 
by multiple pathogens. Other controversial area that remain to be explored is whether 
multiple agents or recurrence of inflammation influence early infection.  
In summary, conflicting results found in the current literature pose a challenge 
when it comes to synthesizing results and generate inferences that apply to the general 
population. There is urgency for additional clinical research and longitudinal studies to 
better understand the activation of the immune system in response to inflammatory-
induced agents and/or mechanisms. Although some preliminary clinical research is 
beginning to explore some possible mechanisms by which inflammation can be linked to 
pathogenic response or a chronic condition, causal factors need to be established. The 
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design for the present study was chosen based upon the existing literature relevant to this 
study and data available and would not allow for determining causality. The next chapter 
provides a description on methodology, instrumentation, study population, sample size, 
and analysis used in this study.  
 
Chapter 3: Research Method 
Study Design and Approach 
In this study, a population-based, cross-sectional design was used to determine 
whether there was an association between two major chronic diseases, T2DM and CVD 
and two herpes viruses, HSV-1, HSV-2. To evaluate whether burden of herpes infections 
(having two or three herpes viruses) has an effect on T2DM or CVD, CMV was added to 
the analysis of burden of infections. In addition, the relationship between (a) T2DM and 
CVD and (b) selected inflammatory markers (CRP, homocysteine, and ferritin) was 
examined. The primary risk factors for both diseases, as identified in the literature 
review, were also evaluated in relationship to the dependent variables under study. 
Twelve years of secondary data (1999-2010) were analyzed to evaluate disease 
prevalence, trends, and associations. Although a cross-sectional design cannot determine 
a causal relationship, this study was expected to add to the literature on the potential 
association between the tested variables. Given the nature of the data, a nonexperimental, 
correlational approach was used. Study participants were randomly selected by a national 
survey and information on variables of interest were collected through three different 
means: a self-reported questionnaire, a physical examination, and clinical data for each of 
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the participants. These three data collection methods provided a means to confirm the 
status of the disease and to validate the data.  
Data Collection and Sample 
 This study used the NHANES data collected from 1999–2010. NHANES, which 
began in 1999 and is conducted every 2 years, is a national probability survey conducted 
by the National Center for Health Statistics, Centers for Disease Control and Prevention 
(CDC, 2012). The survey is designed to estimate the prevalence of common chronic 
conditions and associated risk factors in service of chronic disease prevention. NHANES 
data are the product of a combination of (a) demographic, nutrition, and health-related 
questions and (b) physical examinations that consist of laboratory tests and medical, 
dental, and physiological measurements that are made by highly trained medical 
personnel.  
A national representative sample consisting of approximately five thousands U.S. 
residents is collected by NHANES each year using a complex, multistage, cluster design. 
Health topics collected by NHANES include but not limited to cardiovascular disease, 
kidney disease, obesity, oral health, physical fitness, and sexually transmitted diseases 
(CDC, 2012). A total of 99,806 participants were included in NHANES from 1999-2010, 
from approximately 89 strata (selected surveyed areas) with 2–3 household units—or 
primary sampling units (PSUs)—in each stratum. The final study sample consisted of 
6,706 individuals, aged 20-49, for whom interviews and medical examinations were 
completed, and for which laboratory results were available for all variables of interest.  
43 
 
 
Selection of NHANES Participants and Setting 
 NHANES participants are selected through an algorithm that randomly selects 
neighborhoods based on census information. Approximately 15,000 households are 
screened, 3,500 are selected, and 5,000 residents from the selected households are 
interviewed. Residents of household units are randomly selected and approached by 
interviewers (health, research and academic professionals) to determine their eligibility. 
If a resident agrees to be a part of the study they are scheduled for an interview. The 
interview is conducted in their home and last approximately one hour. Responses are 
recorded on a lap top computer. Individuals 60 and older, African Americans, Hispanics 
and Asians are oversampled in order to increase representation of their population and 
sample reliability (CDC, 2012). Participants also undergo a physical examination by a 
team of health technicians, dentists and doctors in the Mobile Examination Center (MEC) 
which consists of four connecting trailers containing high-tech medical equipment. 
Health exams are given which include measurements of bone density, blood pressure, 
weight and height. Urine and blood samples are collected and tests for health conditions 
such as STIs, anemia, substance use and exposure to environmental chemicals.  
Selection Criteria for Study Participants 
NHANES serological test results for HSV-1 and HSV-2 were available for 
individuals 14-49 years old. Serological data for adolescents 14-17 are restricted and not 
available for public use. Additionally, some of the variables in question were collected 
solely from individuals 20 years and older. As a result, this study was limited to 
NHANES participants between the ages of 20 and 49 for which interviews, medical 
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examination, and laboratory results for all variables of interest were completed. 
NHANES participants whose answers were recorded as don’t know, refused, or missing 
were excluded from the analysis. In addition, some analyses were limited to a specific 
time intervals and subgroups for which the data were available. These include antibody 
for CMV (data available from 1999-2004) and homocysteine (data available from 1999 to 
2006).  
Instrument and Materials 
Secondary quantitative data from NHANES 1999-2010 were used in this study. 
NHANES datasets can be accessed through the CDC website in the NHANES page. 
NHANES begun in the 1960’s, and in 1999 became a continuous program examining 
different health topics and behaviors among various populations. The survey is comprised 
of sociodemographic, dietary and health related questions and also includes physical 
examinations, urine and blood tests to determine the prevalence of major diseases and 
risk factors. The household interview component contains a screener, family interview 
and sample person questionnaire given to individuals in their home (CDC, 2012).  
The Mobile Examination Center (MEC) Questionnaires consist of a MEC Computer-
Assisted Personal Interview (MEC CAPI) and MEC Audio-Computer-Assisted Self 
Interview (MEC A-CASI) where participants can answer questions without the 
interviewer being present. Data is collected using a touch screen lap top computers with 
electronic pens. Interviewers can easily submit information to data servers which are 
available to NCHS staff within 24 hours. The CAPI and CASI programs contain built-in 
quality assurance checks when unrealistic responses are entered. Validity and reliability 
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for all questionnaires are pretested before implementation (CDC, 2012). Additionally, 
laboratory techniques used from 1999 to 2010 to detect enzymes and antibodies to 
studied agents were identical and therefore comparable for trend analysis.  
Justification for Using NHANES Survey Data 
 NHANES is a national survey which data can be used to provide a measurement 
of diagnosed and undiagnosed medical conditions and rates of diseases which can be 
useful in developing public health interventions, programs and policies. NHANES is 
distinctive because it combines survey data with physical examination and clinical data to 
assess the health of the participants and increase the validity of findings. Additionally, 
NHANES data has been systematically implemented since 1999 to report a U.S. 
representative sample of health data. The survey contains information on several different 
health variables which makes it appropriate for this study. NHANES findings have been 
used to determine disease prevalence, develop national standards and health policies and 
design health programs and services demonstrating its relevance and use for the 
population. Table 3 lists dependent, independent, and covariates included in this study.  
 
Table 3 
 
List of Dependent, Independent & Covariates studied, NHANES 1999-2010 
 
Dependent Variables Independent Variables  
of interest 
Covariates 
Diagnosed T2DM 
Diagnosed CVD 
 
CVD related conditions 
CHD 
CHF 
Herpes viruses 
HSV-1 seropositive  
HSV-2 seropositive  
CMV  seropositive 
 
 
Age 
Gender 
Education Level 
Race/Ethnicity 
Household Income 
BMI 
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Angina 
Heart Attack 
MI 
Stroke 
 
Inflammation Markers 
CRP 
Homocysteine 
Ferritin 
Smoking Status 
Hypertension 
Cholesterol 
  
 
 
Selection of Studied Variables 
 Selection of study variables was based on research interest available in NHANES 
1999-2012 surveys. Covariates were selected based on empirical evidence on risk factors 
for both T2DM and CVD. Variables such as age, gender, education and race/ethnicity 
were collected from survey interview data. Physical examinations such as height, weight 
and BMI and laboratory blood tests for HSV-1 and HSV-2 antibodies were conducted by 
MEC (CDC, 2012). Blood was drawn from the participant’s arm via venipuncture to 
obtain laboratory results. In the laboratory, the blood is processed, stored and shipped to 
different laboratories for analysis. The complete blood count (CBC) results are reported 
in the MEC, and all other results are reported from NCHS to the participant. The volume 
of blood drawn is determined by age. For 12 plus years, 115ml of blood is collected from 
participants. Urine samples are collected from participants 6 years old and above.  
Dependent Variables 
T2DM 
 Self-report of T2DM was assessed by the following questions: Have you ever 
been told by a doctor or health professional that you have diabetes or sugar diabetes? 
How old were you when you were told that you had diabetes or sugar diabetes?  
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Respondents input age at the time they were told. Additionally, participants were asked 
about diabetes-related medication, respondents answered yes or no to questions such as 
these: Are you now taking insulin?, For how long have you been taking insulin?, and Are 
you now taking diabetic pills to lower your blood sugar? Only respondents who answered 
questions with a yes or no were included in the analyses; missing values were excluded. 
Clinical diagnosis of T2DM was assessed by evaluating major T2DM indicators. 
Blood sample measures of plasma glucose (500uL/1mL) and glycohemoglobin A1C test 
(400uL) were obtained from participants 12 years and older who were examined in the 
morning sessions. A fasting glucose blood test was performed in all participants 12 years 
and older who were examined in the morning session after a 9-hour fast. After the 
venipuncture, participants are asked to drink 75 milligrams of Trutol® and to have a 
second venipuncture two hours (±15 minutes) after the first venipuncture. 
 Diabetes was defined by at least one of the following criteria: (a) self-report of 
diagnosis by a doctor or other health professional, (b) FBG ≥126 mg/dl, or (c) HbA1C 
≥6.5%. Individuals without diabetes did not meet any of these criteria 
CVD 
 For the purpose of this study, CVD was defined as self-report of diagnosis by a 
doctor or other health professional of coronary heart disease, angina, heart attack, 
congestive heart failure, or stroke. Self-report of CVD was determined by selected 
questions under NHANES medical conditions. CVD questions focused on congestive 
heart failure (CHF), coronary heart disease (CHD), angina (also known as angina 
pectoris), heart attack (also called myocardial infarction or MI), and stroke.  
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CVD questions are as follows: 
 Congestive heart failure questions: Has a doctor or other health professional told you 
that you had congestive heart failure? How old were you when you were told that you 
had congestive heart failure?  
Congestive heart failure questions: Has a doctor or other health professional told you that 
you had congestive heart failure? How old were you when you were told that you had 
congestive heart failure?  
Coronary heart disease questions: Has a doctor or other health professional told you that 
you had coronary heart disease? How old were you when you were told that you had 
coronary heart disease?  
Angina questions: Has a doctor or other health professional told you that you had angina? 
How old were you when you had angina?  
Heart attack or MI questions: Has a doctor or other health professional told you that you 
had a heart attack or MI? How old were you when you had a heart attack or MI?  
Stroke questions: Has a doctor or other health professional told you that you had a 
stroke? How old were you when you had a stroke? Only respondents who answered 
questions with a yes or no were included in the analyses; missing values were excluded. 
Independent Variables 
 The primary independent variables for this study include HSV-1 and HSV-2. 
CMV was added as another independent variable to test the effect of burden of herpes 
infections (HSV-1, HSV-2, and CMV) in T2DM and CVD. Secondary independent 
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variables include three inflammatory markers, C-reactive protein (CRP), Homocysteine 
and serum Ferritin. Evidence-based major risk factors were included as covariates. 
HSV-1 and HSV-2 Seropositivity 
To determine the serostatus for HSV-1 and HSV-2, blood samples of 500uL were 
collected from individuals 14-49 years at the Medical Examination Center (MEC) and 
tested for both HSV-1 and HSV-2 antibodies. However, only test results from 
participants 18 to 49 years of age were available for public use. An enzyme immunoassay 
(EIA) with specific glycoprotein (antigens) to differentiate between HSV-1 and HSV-2 
antibodies was used; however, data for antibodies was limited to only few years. 
Serostatus was recorded as positive or negative. Missing values were excluded. 
HSV-1 and HSV-2 Self-reported 
Self-reported for HSV-1 was not collected in NHANES. A single question to 
determine HSV-2 history was asked to study participants, Has a doctor or other health 
care professional ever told you that you had genital herpes? Due to the fact that genital 
herpes can be caused by HSV-2 and HSV-1, individuals who reported being told they 
have genital herpes were also matched with their serostatus for HSV-1 and HSV-2. 
NHANES clinical data does not differentiate between HSV-1 and HSV-2 for genital 
herpes. Missing values were excluded.   
CMV 
To determine the serostatus for CMV, blood samples of 350uL were collected 
from persons aged 6 to 49 years and tested for CMV antibodies. CMV specific antibody 
was measured with an ELISA assay. Analyses on CMV were limited to a time period of 
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six years given that data were collected solely from 1999 to 2004. Test results for 
participants aged 20 to 49 were available for public use and included in the study 
analysis. Serostatus for CMV was recorded as positive or negative. Missing values were 
excluded. 
Inflammatory Markers 
Inflammatory markers also known as biomarkers are useful clinical diagnostic 
and prognostic tools for ruling out specific conditions. For example, elevated levels of 
CRP, a protein synthesized by the liver, is an indication of inflammation present in the 
body and has been used as a biomarker for the risk of CVD and T2DM (Ballantyne et al., 
2005; Davidson, 2011; Ridker et al., 2000; Watson et al., 2012). Interleukin or IL-6, a 
protein-coding gene, functions with inflammation in response to harmful stimuli such as 
infection (Ridker et al., 2000I). L-6 marker was not collected by NHANES and therefore 
not included in the study. Fibrinogen, a protein synthesized by the liver, helps to stop 
clots to form by converting thrombin into fibrin and may indicate a risk for diabetes. 
Fibrinogen data was collected for only few years and therefore not included in study 
analysis. Elevated levels of Ferritin, a protein that controls the levels of iron in the blood, 
may be an indication of inflammation, heart failure, diabetes and other conditions 
(Oshaug et al., 1995; Ridker et al., 2000). Elevated levels of Homocysteine, an amino 
acid found in the blood plasma, may increase the risk for heart disease (Ridker et al., 
2000).  
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CRP 
 Approximately 300uL of blood samples from individuals 3 years and older were 
used to measure the levels of CRP. The following predictive values were used for CVD: 
Normal levels of CRP range from 0 to 1.0 mg/dl. Elevated high sensitivity CRP (hsCRP) 
levels associated with CVD and other chronic diseases. Any hsCRP level less than 1.0 
mg/L is considered low risk; average risk is considered between 1.0 and 3.0 mg/L; and 
elevated hsCRP levels and highest risk are considered more than 3.0 mg/L. The median 
concentration of the study population was used as the cut off for both CVD and T2DM 
when applicable.  
Homocysteine 
Plasma homocysteine is a nonprotein amino acid. Blood samples of 1.25mL were tested 
from individuals 1 year and older. Analysis for homocysteine were limited to a time 
interval of eight years given that data was collected only from 1999 to 2006. For the 
purpose of this study, the median value of homocysteine in the study population was used 
as a cut off when applicable. 
Ferritin 
The level of serum ferritin is directly related to the amount of iron stored in the body. 
Blood samples of 1.25mL were tested from individuals 1 year and older. Normal values 
of Ferritin may vary from lab to lab and in the clinical field in general. For this study, the 
median value of ferritin in the study population was used as a cut off when applicable. 
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Covariates 
Age 
 Age was determined in the questionnaire by the date of birth given by 
participants. Respondents who answered don’t know or refused to answer were coded as 
missing and excluded from the analysis. Analyses were limited to participants ages 20-49 
due to data availability. 
Gender  
Participants were asked in the questionnaire to select if they were male or female.  
Respondents who answered don’t know or refused to answer were coded as missing and 
excluded from the analysis. 
Education Level  
Respondents were asked in the questionnaire: What is the highest grade or level 
of school that you have completed or the highest degree you have received? Education 
levels were divided into two categories: individuals who completed high school and those 
who had college level. Respondents who answered don’t know, refused or the answer 
was coded as missing were excluded from the analysis. 
Race/Ethnicity 
 Respondents were asked in the questionnaire: What race do you consider yourself 
to be? NHANES used five categories: nonHispanic White, nonHispanic Black, Mexican 
American, Other and Other Hispanics and could only select one. Respondents who 
answered don’t know, refused or answer was coded as missing were excluded from the 
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analysis. Due to frequency distribution limitations with multi-categorical variables, race 
was recategorized as nonwhites versus whites for binary logistic regression. 
Household Income 
 In the questionnaire, family was described as: Individuals and groups of 
individuals who are related by birth, marriage or adoption. Stepchildren, parents or 
siblings are included. It also includes unmarried partners if they have a biological or 
adoptive child in common. Participants were asked  about the total income for you and 
your family members in the last calendar year- including income from all sources we 
have just talked about such as wages, salaries, social security or retirement benefits, help 
from relatives and so forth. Can you tell me that amount before taxes? Respondents 
entered the amount of income. In this study household income was categorized as follow: 
income from 0 to 24, 999; income from 25, 000 to 54, 999; income over 55, 000. 
Respondents who answered, don’t know, refused or answer was coded as missing were 
excluded from the analysis. 
BMI 
 The body mass index (BMI) was calculated using participants’ body weight and height 
(weight divided by height). In this study, BMI <25 was categorized as normal weight; 
BMI ≤25 and <30 as overweight; and BMI≥30 was considered obese. Respondents who 
answered, don’t know, refused, or answer was coded as missing were excluded from the 
analysis. 
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Smoking Status 
  Smoking status was determined by asking, have you smoked at least 100 
cigarettes in your entire life? Respondents answered yes or no. They were also asked, Do 
you now smoke cigarettes: every day, some days or not at all? Respondents answer yes or 
no. Only respondents who answered questions with a yes or no were included in the 
analyses. Smoking status was categorized in the analysis as follows: never smoke; past 
smoker; and current smoker. 
Hypertension /Blood Pressure 
  Self-reported high blood pressure of the participants was assessed by the 
following questions: Have you ever been told by a doctor or other health professional that 
you had hypertension, also called high blood pressure? Respondents answered, yes or no 
to questions such as Have you been told on 2 or more different visits that you had 
hypertension, also called high blood pressure?, because of your blood pressure have you 
been told to take prescribed medicine? Are you now taking prescribed medication? 
Respondents were also asked, what age were you told that you had high blood pressure? 
Only respondents who answered questions with a yes or no were included in the analyses. 
Physical measurements of systolic and diastolic BP consisting of up to 4 different BP 
readings in different time intervals were collected from survey participants. For the 
purpose of this study, the 2nd reading was selected as a better estimate for measuring BP 
among participants. 
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Cholesterol 
           Self-reported cholesterol levels were assessed. Respondents answered yes or no to 
the following questions: Have you ever been told by a doctor or other health professional 
that your cholesterol was too high? To lower your blood cholesterol, have you ever been 
told by a doctor or other health professional to take prescribed medicine? and Are you 
now following this advice to take prescribed medicine? Only respondents who answered 
questions with a yes or no were included in the analyses.  
For physical examinations total cholesterol, HDL- cholesterol, LDL-cholesterol 
were measured through blood lipid levels of 1mL from individuals 12 and older. Total 
cholesterol was calculated from totals of HDL and LDL levels. For analysis purposes, the 
median of total cholesterol, HDL and LDL values in the study population were used. 
Statistical Analysis 
This study employs secondary data from the CDC NHANES database and utilizes 
a cross-sectional design, which provides the means for conducting descriptive and 
inferential analysis. First, simple descriptive statistics to examine the distribution of the 
study sample (N=6,706) such as means, standard deviations, and proportions (when 
appropriate) for the main outcome variables (T2DM and CVD) and explanatory variables 
(demographic and clinical variables) were applied. Second, a binary analysis and chi-
square test was used to determine the relation between the two dependent variables and 
categorical predictors. Given that NHANES provides a large representative sample for 
conducting secondary research studies, statistical hypothesis testing power is not a 
concern for the analyses needed in this study. Multiple logistic and stepwise regression 
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analyses adjusting for demographic and clinical variables was applied for confounding 
factors using continuous waves of NHANES data from 1999 to 2010.  
All statistical analyses were performed in SAS-Callable SUDAAN, Release 
11.0.1. (RTI, 2013). A reference table that included all study variables names, SAS data 
files, and relevant codebook and documentation was used for accuracy and validity. 
NHANES data files were imported from the CDC NHANES website located at 
http://www. NCHS.gov and saved in a preassigned library in SAS v9.3. (SAS, 2000-
2004). Once all of the needed variables were downloaded into the SAS library, data were 
merged by SEQN ID, recoded and categorized when necessary for analysis purposes. 
Analytical recommendations from NHANES for sample weights and variables of interest 
were used. Descriptive analysis was performed on independent, dependent, and covariate 
variables. When necessary and applicable, study variables were dichotomized at the 
median value defined by the studied population into either low to normal or average to 
high levels. The high and average levels of CRP were combined given that the frequency 
in the high group was small, and there were too many missing once the weight variable 
was applied. A similar approach was used with ferritin levels due to small sample size in 
the high and low levels of ferritin for men and women. Therefore, CRP was recategorized 
into high or average levels versus low or normal levels, and ferritin levels for men and 
women were combined and recategorized as high versus low and normal versus low in 
the multivariate regression analyses. 
To determine the relationship between two categorical variables, a standard 
Pearson’s Chi-square test was performed and to determine the relationship between two 
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continuous variables, the standard t-test was used. To test the hypothesis of association 
between HSV and T2DM and CVD, logistic and stepwise regression analyses were 
performed (Draper, & Smith, 1981; Hocking, 1976). Adjustments were made to control 
for potential confounding factors and calculate the adjusted odds ratio and respective 
95% confidence interval (CI). Primary independent variables and covariates were entered 
into four different models. In the 1st model, crude rates for all independent variables and 
covariates were calculated. In the 2nd model, adjusted rates for all the independent 
variables and covariates were calculated. In the 3rd and 4th models, the most predictive 
independent variables and covariates were included in each group. The 3rd and 4th models 
consisted of different stages. At first stage, the primary independent variable, HSV-2, was 
entered into the model. Then a forward stepwise regression was performed to add the 
most predictive demographic variables (second stage). Significant demographic variables 
such as age, gender and household income were added into the model at this stage. After 
adjusting for these variables, additional clinical variables were added into a final model 
(third stage). Since the final model (column 4 in odds ratio tables for T2DM and CVD) 
removes the effect of all possible confounders, this model provides the best effect 
estimates. Overall associations were represented by values p ≤ 0.10, p ≤ 0.05, p < 0.01.  
The PROC RLOGIST (RTI, 2013) was used to model the risk of T2DM and CVD 
as a function of HSV-1 and HSV-2; HSV (the combination of HSV-1 and HSV-2 was 
defined as 0 = neither HSV-1 nor HSV-2, 1 = HSV-1 or HSV-2, 2 = HSV-1+HSV-2,      
3 = HSV-1+HSV-2+CMV); and burden of herpes infection was defined as 0, 1, 2, 3 
adjusted by demographic covariates, age, gender, race, educational status, household 
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income, and smoking, and clinical covariates blood pressure, body mass index (BMI), 
blood cholesterol level, C reactive protein (CRP) and ferritin (Tables 4, 5, 6 and 7). In 
addition, the PROC CROSSTAB (RTI, 2013) was used to evaluate the prevalence 
difference of T2DM and CVD among different categories of explanatory variables 
without adjusting by age, and the PROC DESCRIPT (RTI, 2013) was used to evaluate 
the prevalence difference of T2DM and CVD among different categories of explanatory 
variables adjusted by age. For all of three procedures above, the nest, weight and subpopn 
statements were used (Tables 2 and 3). The nest statement with strata (sdmvstra) and 
PSU (sdmvpsu) was used to account for the design effects. The weight statement with 
weight variable FASTWGT was used to account for the unequal probability of sampling 
and nonresponse. The subpopn statement was used to select the sample individuals 20 or 
older and less than 50 years (20 ≤ age < 50) because only those individuals are of interest 
in this study.  
The research questions are listed below again for review.  
H11: Is HSV-1 infection associated with higher risk of developing T2DM? 
H01: HSV-1 infection is not associated with higher risk for T2DM. 
H12: Is HSV-2 infection associated with higher risk for of developing T2DM? 
H02: HSV-2 infection is not associated with higher risk for T2DM. 
H13: Is HSV-1 infection associated with higher risk of developing CVD? 
H03: HSV-1 infection is not associated with higher risk for CVD. 
H14: Is HSV-2 infection associated with higher risk of developing CVD?  
H04: HSV-2 infection is not associated with higher risk for CVD. 
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H15: Is having a higher burden of pathogens (HSV-1 + HSV-2+CMV) associated with a 
higher risk of developing T2DM and/or CVD? 
H05: A higher burden of pathogens is not associated with higher risk for T2DM and/or 
CVD. 
Bias and Delimitations 
Given that this study utilized data collected from a cross-sectional design, the study 
cannot prove causality. Only participants whose data were available between the ages of 
20 and 49 with positive serology test for HSV-1 and HSV-2 and diagnosed with T2DM 
and CVD were included in the study. Some analyses were restricted to subpopulations for 
which the studied variables were collected. While data for HSV, T2DM and CVD were 
collected for 12 years period (1999-2010), serological status for other herpes viruses 
associated with inflammatory diseases such as CMV were available only for 4 years 
(1999-2004), which limited the opportunities for comparison and correlation analysis. In 
addition, data for some of the inflammatory markers were not collected consistently for 
the 12 years period; therefore, some analyses were restricted by this limitation.    
Potential Bias 
Selection Bias 
NHANES selects survey participants randomly from a large cross-sectional study 
sample, which allows for making inferences for the general population. As a result, 
selection bias is not a concern. 
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Information Bias 
Self-report bias may be a limitation of NHANES data given that the interview 
questions are based on information recall of the participants. Participants may provide 
biased information when he or she cannot recall or may modify the information when 
asked by the interviewer. Nevertheless, for the purpose of this study, the main variables 
of interest (HSV, CMV, T2DM, CVD, CRP, homocysteine, serum ferritin) were 
measured by laboratory and examination results rather than self-report alone. NHANES 
laboratory methods are conducted with high performance instruments and following strict 
protocols.  
Confounding 
A multivariate analysis was performed on variables of interest, which allows 
identifying potential cofounder factors.  
Type I and Type II error 
To control for type I error, a margin of error was set at alpha 0.05, with a 
probability of accuracy of 95%. Since a large sample size of 6,706 was used in the 
present study, type II error is not a concern. 
Ethical Considerations 
NHANES survey has ongoing Institutional Review Board (IRB) approval through 
the National Center for Health Statistics (NCHS) Research Ethics Review Board. The 
IRB ensures that ethical, biomedical and behavioral research best practices involving 
humans are in place before, during and after research studies are conducted with humans. 
By law, NHANES adheres to a rigorous review process in making certain that human 
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subject’s identity is kept confidential and anonymous. In fact, all personal identifiers are 
removed from NHANES data prior publishing. Written consent is obtained from each 
survey participants. In a case of a minor, consent is obtained from parents or legal 
guardian. Given that I used publicly available secondary data with no link to personal 
identifiers, this study poses no physical or emotional risk or benefit directly or indirect to 
survey participants (CDC, 2012). IRB approval number for this study is 12-09-13-
0075602. 
Summary  
           This study used a cross-sectional population based designed and a large sample 
size from the CDC NHANES (1999-2010) dataset. Independent and dependent variables 
as well as covariates were selected based on a comprehensive literature review. Given the 
type and number of variables selected for this study, chi square was applied in univariate 
analysis whereas multivariate logistic and stepwise regression analyses were employed to 
examine the relationship between HSV and T2DM; the relationship between HSV and 
CVD; and the effects of burden of infections (having more than one herpes virus) on 
T2DM and CVD. The relationship between T2DM and CVD and selected inflammatory 
markers and covariates was also evaluated. Several statistical models were used to test 
study hypotheses of association. Adjustments for possible confounding factors were 
performed in all the analyses. Lastly, since this study used 12 years of data from a 
national representative sample, results and findings from this study can be applied to the 
general population. 
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                                                        Chapter 4: Results 
Introduction  
This study examined whether being HSV-1 or HSV-2 seropositive increases the 
risk of developing T2DM and/or CVD; and whether being seropositive to both HSVs or 
to three herpes viruses (HSV and CMV) increases the risk of developing T2DM and/or 
CVD. Further, this study evaluated whether a relationship exists among T2DM and CVD 
and CRP, serum ferritin, and homocysteine. It used a representative sample from 
participants in the United States.  A cross-sectional design was used with NHANES data 
from 1999-2010. During that period, 99,806 participants were studied. The sample size 
for this study consisted of 6,706 participants, aged 20-49, who met the criteria and data 
from interviews, medical examination, and laboratory were available.  Also evaluated 
were the estimates for the prevalence of each of the primary independent and dependent 
variables as well as for the covariates. Chapter 4 discusses the study results; important 
findings are presented in graphs and tables, which include the characteristics and 
distribution of the study population, the distribution of the herpes viruses understudy, the 
prevalence of T2DM and CVD in the sample, and the relationship among T2DM and 
CVD and HSV-2. The findings are summarized at the end of the chapter.  
Demographic and Health Characteristics of Study Population 
The distribution of the study population is described in Table 4. The average age 
was 35 years with slightly more between 35-49 years old (52.6%) than 20-34 years old 
(47.4%). The sample was equally divided between males (49.7%) and females (50.3%). 
The majority of participants were nonHispanic Whites (65.8%), followed by Hispanics 
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(16.9%), nonHispanic Blacks (12.5%), and other racial populations (4.9%). The 
participants were well educated, with more than half having earned a college degree 
(57.8%) and only slightly less having completed high school (42.3%). Most participants 
had incomes well above poverty, with nearly half earning annually more than $55,000 
(47.0%) and about one-third between $25,000-54,000 (31.9%). The majority of 
participants were nonsmokers (55.2 %). Clinical data indicated that nearly all of the 
participants (91.8%) were not hypertensive; however, only 36.9% had a normal BMI 
(less than 25). The rest of the participants were either overweight (32.4% with a BMI   
25-29) or obese (30.8 % with a BMI ≥ 30). Nearly all participants had low-normal CRP 
levels (90.5 %). Overall, ferritin levels for participants were normal with the majority of 
men (83.3 %) and women (94.7%) in the low to normal range. Most participants had 
normal (97.3%) homocysteine levels and a few (2.7%) had moderate levels. Since no 
participants had elevated levels of homocysteine, this marker was excluded from 
association analyses. More than half of the participants had cholesterol levels that were 
desirable (61.0%); about one-quarter had borderline (26.9%) and only 12.0 % had high 
cholesterol levels.  
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Table 4 
 
 Demographic and Health Characteristics, NHANES, 1999-2010  
 
Characteristics  nα Percentage (95% CI) 
Total Population   6706  
Age Mean   34.92 [34.58,35.26] 
Gender    
Male  3106 49.68 [48.63,50.73] 
Female  3600 50.32 [49.27,51.37] 
Race/Ethnicity    
NonHispanic White  2931 65.80 [63.06,68.44] 
NonHispanic Black  1376 12.47 [11.00,14.12] 
Hispanic  1958 16.85 [14.84,19.06] 
Other  441 4.88 [3.98,5.98] 
Age (years)    
20~34  3401 47.37 [45.49,49.27] 
35~49  3305 52.63 [50.73,54.51] 
Education    
High School  3325 42.25 [39.94,44.60] 
College or higher  3373 57.75 [55.40,60.06] 
Household Income    
<25,000  1014 21.11 [18.99,23.40] 
25,000~54,000  1347 31.85 [29.36,34.45] 
>55,000  1522 47.04 [44.16,49.94] 
Smoking Status    
Nonsmoker  3884 55.23 [53.17,57.28] 
Smoker  2817 44.77 [42.72,46.84] 
Hypertension    
Yes  502 8.25 [7.54,9.03] 
No  5360 91.75 [90.97,92.47] 
BMI(kg/m2)    
<25 (normal)  2223 36.87 [35.42,38.35] 
25~29 (overweight)  2213 32.37 [30.87,33.92] 
≥30 (obese)  2201 30.76 [29.25,32.30] 
CRP Levels    
Low-Normal  5949 90.50[89.77,91.19] 
Average  651 8.32 [7.62,9.08] 
High  80 1.18 [0.88,1.58] 
Ferritin Levels (Men)    
Low  9 1.05 [0.47,2.32] 
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Normal  881 82.25 [79.23,84.92] 
High  160 16.69 [14.16,19.58] 
Ferritin Levels (Women)    
Low  779 20.28 [18.69,21.96] 
Normal  2133 74.46 [72.46,76.37] 
High  140 5.26 [4.30,6.43] 
Homocysteine Levelsb    
Normal  2003 97.33 [96.28,98.09] 
Moderate     46 2.67 [1.91,3.72] 
Elevated  0  
Cholesterol Levels    
< 200 (normal)  3936 61.03 [59.60, 62.44] 
200~239 (borderline)  1849 26.93 [25.65,28.26] 
≥240 (high)   870 12.04[11.00,13.15] 
α Data are missing for all variables except for age, gender, and race/ethnicity.                                                                                    
b Data available only for 1999-2006, homocysteine was excluded from association 
analyses. 
 
Distribution of Herpes Viruses 
 
Overall, a decline in all three herpes viruses (HSV-1, HSV-2, CMV) was 
observed in this sample population from 1999 (HSV 62.4%, 23.7%) to 2010 (HSV 
54.2%, 17.2%) respectively (Figure 4). A decline was also observed in CMV from 1999 
(56.7%) to 2004 (53.0%). A similar trend was observed among the participants who were 
seropositive to both, HSV-1and HSV-2 (14.8% in 1999) to (10.6% in 2010) and among 
the participants who were positive to HSV and CMV (11.3% in 1999) to (8.5% in 2004).  
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Figure 4. Percentage of participants seropositive for HSV-1, HSV-2, HSV-1+HSV-2, 
CMV, and all three herpes from 1999-2010 in this U.S. population sample. Data for 
CMV and burden of infection (three herpes viruses HSV and CMV) is not available after 
2004.  
 
In this study, more females than males were seropositive to all herpes virus 
infections, with females having almost double the number of HSV-2 infections, 990 
(26.4%) vs 499 (13.45) and HSV-1and HSV-2 infections, 669 (16.5%) vs 309 (7.55) than 
males (Figure 5). A slightly difference was observed in the proportions of HSV-1 and 
CMV among females, 2,391 (61.7%) vs 1,144 (62.1%) and among males, 1,932 (56.9%) 
vs 823 (47.9%) respectively. 
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Figure 5. Number of participants seropositive for HSV-1, HSV-2, HSV-1and            
HSV-2, and CMV by gender from 1999-2010. CMV data only available from 1999-2004. 
 
Results of this study indicated that CMV and HSV-1 were predominantly high 
across all racial groups (Figure 6). Particularly, HSV-1 was high among Hispanics 
(79.2%), followed by other race groups (77.9%), nonHispanic Blacks, and nonHispanic 
Whites (51.8%). Similarly, CMV was higher among other ethnic populations (84.6%) 
and Hispanics (80.9%), followed by nonHispanic Blacks (77.7%). CMV was far less 
common among nonHispanic Whites (43.0%). In comparison to all racial groups, a 
higher proportion of nonHispanic Blacks were seropositive to HSV-2 (46.7%) and HSV-
1and HSV-2 (30.0%), followed by other racial groups (HSV-2, 29.2%) and (HSV-
1+HSV-2, 23.4%).  
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Figure 6. Percentage of participants seropositive for HSV-1, HSV-2 and CMV by 
ethnicity from 1999-2010. CMV data only available from 1999-2004. 
 
 
All herpes virus infections were higher among individuals between the ages of 35-
49, with this group having almost twice the number of HSV-2, 976 (26.3%) vs 
513(12.9%) and over twice the number of HSV-1and HSV-2, 674(16.6%) vs 304(7.0%) 
(Figure 7). A slightly difference was observed between individuals aged 20-35 and 35-49 
that were seropositive to HSV-1, 2,027 (53.3%) vs 2,296 (64.8%) and CMV, 954 (51.3%) 
vs 1013 (58.3%) respectively.  
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Figure 7. Percentage of participants seropositive for HSV-1, HSV-2 and CMV by age 
groups from 1999-2010. CMV data only available from 1999-2004. 
 
 
Prevalence of T2DM and CVD by Selected Health Characteristics 
The prevalence of T2DM and CVD among selected characteristics in the study 
sample was examined using Pearson chi-square test (Figure 5). An elevated prevalence of 
T2DM was observed in gender, race/ethnicity, age, household income, hypertension, and 
BMI. Particularly, the age-adjusted prevalence of T2DM was significantly higher in 
males 5.13% [95% CI=4.14, 6.35] than in females 3.70% [95% CI = 2.97,4.60]; 
significantly higher among Hispanics 6.62% [95% CI = 5.03, 8.66], followed by other 
racial groups, 6.22% [95% CI = 3.83, 9.95]; and nonHispanic Blacks 6.12% [95% 
CI=4.89, 7.64] compared to nonHispanic Whites, 3.51% [95% CI = 2.74,4.49]. T2DM 
was over three times higher in individuals aged 35-49, 6.63% [95% CI = 5.53, 7.93] than 
among aged 20-34, 1.78% [95% CI = 1.36, 2.34]; significantly higher among individuals 
0%
10%
20%
30%
40%
50%
60%
70%
HSV1 HSV2 HSV1 + 2 CMV
20-34
35-49
70 
 
 
with a household income between 25,000 and 54,999, 6.22% [95% CI = 4.53,8.48], and 
with an income less than 25,000 6.06% [95% C I= 4.34, 8.39] than among individuals 
with income ≥55,000; and more than two fold higher among individuals with 
hypertension 9.44 [95% CI = 6.46, 13.6] than those without hypertension 3.72%        
[95% CI=3.08,4.49]. Higher prevalence was found among obese individuals with a BMI 
≥30 8.80% [95% CI = 7.36, 10.5]; followed by overweight individuals with a BMI 25-29 
2.91% [95% CI = 2.14, 3.95] than among individuals with a BMI ≤ 25. However, no 
difference was observed in the prevalence of T2DM and education, smoking status, or 
cholesterol levels. 
Similarly, the age-adjusted prevalence of CVD was found higher among 
individuals aged 35-49, 3.60% [95% CI = 2.89,4.48] than among the younger group; with 
a household income less than 25,000, 3.82% [95% CI = 2.40,6.02]; followed by 
individuals with a household income between 25,000-54,999, 2.92% [95% CI=1.99,4.25] 
than among individuals with an income ≥ 55,000; with hypertension 3.66% [95% 
CI=2.31, 5.76] than among individuals without hypertension; among obese individuals 
(BMI ≥30), 3.39% [95% CI = 2.58, 4.44], followed by individuals overweight (BMI 
between 25-29) 2.12% [95% CI = 1.49, 2.99] than among individuals with a BMI ≤25. In 
contrast to T2DM, CVD was significantly higher among individuals with a high school 
education 3.00% [95% CI = 2.35, 3.84] compared to those with a college or higher 
degree 1.80% [95% CI = 1.31, 2.48]; and among individuals that smoke or are past 
smokers 3.65% [95% CI = 2.90, 4.59] in comparison to those that never smoke. The 
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prevalence of CVD was not significantly different by gender, race/ethnicity, or 
cholesterol level.  
 
 
Table 5 
 
Prevalence (%) of Reported T2DM and CVD among U.S. 20 to 49 Years Old by Selected 
Characteristics, NHANES, 1999-2010   
 
Characteristics T2DM 
Unadjusted 
(95%CI) 
T2DM 
Age-Adjusted 
(95% CI) 
CVD 
Unadjusted 
(95%CI) 
CVD 
Age-Adjusted 
(95% CI) 
Gender ** **   
  Male 5.01 [4.03,6.20] 5.13[4.14,6.35] 2.12[1.64,2.75] 2.19[1.68,2.83] 
  Female 3.67[2.95,4.57] 3.70[2.97,4.60] 2.39[1.78,3.21] 2.41[1.79,3.24] 
Race/Ethnicity *** ***   
  NonHispanic White 3.57[2.79,4.56] 3.51[2.74,4.49] 2.39[1.82,3.13] 2.34[1.78,3.07] 
  NonHispanic Black  5.90[4.72,7.36] 6.12[4.89,7.64] 2.79[2.01,3.84] 2.93[2.15,3.99] 
  Hispanic    5.72[4.28,7.61] 6.62[5.03,8.66] 1.60[1.10,2.32] 1.73[1.18,2.52] 
  Other 5.94[3.63,9.59] 6.22[3.83,9.95] 1.46[0.61,3.46] 1.59[0.66,3.78] 
Age (years) *** *** *** *** 
  20~34 1.78[1.36,2.34] 1.78[1.36,2.34] 0.77[0.51,1.17] 0.77[0.51,1.17] 
  35~49 6.63[5.53,7.93] 6.63[5.53,7.93] 3.60[2.90,4.48] 3.60[2.89,4.48] 
Education   ** ** 
  High School 4.62[3.78,5.62] 4.79[3.96,5.79] 2.89[2.26,3.69] 3.00[2.35,3.84] 
  College or higher 4.14[3.29,5.20] 4.14[3.28,5.21] 1.80[1.31,2.48] 1.80[1.31,2.48] 
Household Income ** ** *** *** 
  <25,000 5.48[3.85,7.73] 6.06[4.34,8.39] 3.43[2.16,5.43] 3.82[2.40,6.02] 
  25,000,54,000 5.81[4.25,7.89] 6.22[4.53,8.48] 2.68[1.82,3.92] 2.92[1.99,4.25] 
  >55,000 2.98[1.97,4.50] 2.77[1.81,4.22] 1.56[1.00,2.46] 1.45[0.92,2.27] 
Smoking Status   *** *** 
  Never smoke 4.01[3.30,4.87] 4.20[3.44,5.11] 1.05[0.74,1.50] 1.10[0.77,1.56] 
  Past or current                                           
Smoke 
4.75[3.84,5.85] 4.64[3.75,5.72] 3.75[2.98,4.72] 3.65[2.90,4.59] 
Hypertension *** *** ** ** 
  Yes 10.48[7.60,14.28]  9.44[6.46,13.6] 4.79[3.01,7.54] 3.66[2.31,5.76] 
  No 3.59[2.97,4.33] 3.72[3.08,4.49] 2.03[1.57,2.61] 2.11[1.63,2.71] 
BMI(kg/m2) *** *** *** *** 
  <25 1.31[0.87,1.98] 1.46[0.96,2.20] 1.11[0.70,1.75] 1.21[0.75,1.94] 
  25,29 2.96[2.18,4.01] 2.91[2.14,3.95] 2.16[1.52,3.06] 2.12[1.49,2.99] 
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  ≥30  9.08[7.60,10.83]  8.80[7.36,10.5] 3.52[2.67,4.62] 3.39[2.58,4.44] 
Cholesterol Levels     
  < 200 4.04[3.32,4.91] 4.52[3.70,5.50] 2.09[1.63,2.68] 2.34[1.83,2.99] 
  200-239 4.41[3.23,5.99] 4.13[3.04,5.60] 2.23[1.53,3.24] 2.07[1.42,3.00] 
  ≥240 5.28 [3.79,7.31] 4.73[3.38,6.59] 2.96[1.76,4.93] 2.31[1.37,3.87] 
*p < 0.10, ** p < 0.05, ***p < 0.01 
 
 
The prevalence of T2DM and CVD by each of the herpes virus infections and 
selected inflammatory markers is illustrated (Table 6). Results indicated that the 
prevalence of T2DM and CVD was significantly higher among individuals seropositive 
to HSV-2, 5.54% [95% CI = 4.36, 7.01] and 3.32% [95% CI = 2.36, 4.65] respectively, 
but not to HSV-1 or CMV. Age-adjusted prevalence of T2DM was significantly elevated 
among individuals with average to high CRP levels 10.9% [95% CI = 8.11, 14.5] than 
individuals with low-normal levels 3.63% [95% C I= 3.05, 4.33]; among males with high 
ferritin levels 7.85% [95% CI = 3.68, 15.96] than males with normal levels 5.32% [95% 
CI = 3.34, 8.37] and among females with high levels 12.6% (95% CI = 6.11, 24.07). 
There was no data for low ferritin levels among males. Further, the prevalence of CVD 
was higher among females with high 4.85% [95% C I= 2.53, 9.09] ferritin levels. No 
relationship was observed between the prevalence of CVD and CRP, male’s ferritin 
levels, or homocysteine neither between T2DM and homocysteine levels. There was no 
data of elevated homocysteine levels for T2DM or CVD; therefore, homocysteine was 
excluded from logistic regression analyses. 
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Table 6 
 
Prevalence (%) of T2DM and CVD Among U.S. 20 to 49 Years Old by Herpes Viruses 
Infections and Selected Inflammatory Markers, NHANES 
 
Characteristics T2DM 
Unadjusted 
(95%CI) 
T2DM 
Age-adjusted 
(95% CI) 
CVD 
Unadjusted 
(95%CI) 
CVD 
Age-Adjusted 
(95% CI) 
HSV-1     
Yes 4.56[3.79,5.48] 4.40[3.66,5.29] 2.44[1.90,3.11] 2.36[1.85,3.01] 
No 3.86[2.96,5.02] 4.26[3.24,5.57] 2.01[1.47,2.75] 2.29[1.67,3.15] 
HSV-2 *** *** *** *** 
Yes 6.15[4.87,7.75] 5.54[4.36,7.01] 3.96[2.82,5.52] 3.32[2.36,4.65] 
No 3.80[3.13,4.62] 4.06[3.32,4.96] 1.85[1.46,2.33] 1.97[1.56,2.49] 
CMV a     
Yes 4.30[3.08,6.00] 4.16[3.03,5.70] 1.97[1.31,2.96] 1.92[1.28,2.85] 
No 4.27[2.97,6.09] 4.47[3.08,6.45] 1.90[1.13,3.19] 2.05[1.20,3.49] 
CRP *** ***   
Low-Normal 3.56[2.99,4.24] 3.63[3.05,4.33] 2.07[1.65,2.59] 2.11[1.69,2.64] 
Average to High 11.1[8.21,11.9] 10.9[8.11,14.5] 3.84[2.44,6.00] 3.74[2.41,5.76] 
Ferritin Levels 
(Males) 
** **   
Low      0.00 0.00 0.00 0.00 
Normal 5.11[3.23,8.00] 5.32[3.34,8.37] 2.32[1.32,4.03] 2.39[1.36,4.19] 
High     8.93[4.06,18.52] 7.85[3.68,15.96] 3.67[1.53,8.53] 2.90[1.18,6.93] 
Ferritin Levels 
(Females) 
*** *** * * 
Low      2.36[1.55,3.57] 2.49[1.62,3.80] 1.72[0.82,3.57] 1.77[0.84,3.70] 
Normal 3.32[2.47,4.45] 3.38[2.53,4.51] 2.26[1.52,3.34] 2.32[1.56,3.44] 
High     12.15[7.08,20.08] 12.56[6.11,24.07] 6.34[3.30,11.85] 4.85[2.53,9.09] 
Homocysteine 
Levelsb 
    
Normal 4.05[2.94,5.56] 4.10[2.99,5.62] 2.81[1.94,4.07] 2.88[1.97,4.17] 
Moderate 7.42[3.04,17.04] 5.74[2.24,13.91] 5.66[1.56,18.54] 6.66[1.63,23.50] 
Elevated 0.00 0.00 0.00 0.00 
*p < 0.10, ** p < 0.05, ***p < 0.01 
a Data available only for 1999-2004 
b Data available only for 1999-2006 
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Relationship Between T2DM and HSV 
The relationship between T2DM and HSV-2 as well as demographic and clinical 
variables was explored (Table 7). Results from the logistic regression analysis (crude 
odds ratios) showed that T2DM was associated with HSV-2, age, gender, race, household 
income, blood pressure, BMI, CRP, and ferritin. Specifically, T2DM was 1.66 times 
more likely to occur among individuals who were HSV-2 positive than among 
individuals who were not (p = 0.0010) if not adjusted by any factor (Column 1 Table 7). 
The odd ratio between T2DM and HSV-2 adjusted for each of demographic and clinical 
variables were also calculated (Column 2, Table 7). T2DM was 1.81 times more likely to 
occur among individuals who were HSV-2 positive than among individuals who were not 
if adjusted by gender (p = 0.0001); 1.52 adjusted by race (p = 0.0048); 1.65 (p = 0.0011) 
adjusted by education; 1.63 (p = 0.0012) adjusted by smoking; 1.67 (p = 0.0003) adjusted 
by blood pressure; 1.48 (p = 0.0150) adjusted by BMI;  1.64 (p = 0.0014) adjusted by 
cholesterol level;  1.53 (p = 0.0054) adjusted by CRP; and 2.11 if adjusted by ferritin (p = 
0.0008). Based on the confounding 10% rule (Vittinghoff, Glidden, Shiboski, & 
McCulloch, 2012), it was observed that gender and ferritin were positive confounders, 
while age, income and BMI were negative confounders of HSV-2.  
To examine the predictive effects of multiple variables simultaneously, a stepwise 
regression was performed (Columns 3 and 4, Table 7). After adjusting for all potential 
predictive demographic variables for T2DM (age, gender, household income, BMI, CRP, 
and ferritin), the association between T2DM and HSV-2 was no longer significant. 
However, all confounding factors included in the regression model (Table 7) were 
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significant at either alpha=0.10, 0.05, or 0.01. The presence of confounding implies that 
the adjusted summary measure is a better estimate of the effect of the exposure on the 
outcome of interest since it removes the effect of all possible confounders. Therefore, 
model 4 (column 4, tables 7) provides the best effect estimate and confirms the null 
results. 
 
Table 7 
 
Odds Ratios (95% Confidence Intervals) for T2DM Associated With HSV-2 by Selected 
Characteristics Among U.S. 20 to 49 Years Old Population, NHANES, 1999-2010  
 
 
Ref (negative) 
(1) Crudea 
1.00 
(2) Adjustedb 
1.00 
(3) Adjustedc 
1.00 
(4) Adjustedd  
1.00 
HSV-2  (positive)  1.66[1.23,2.23]*** 1.66[1.23,2.23]*** 1.02[0.67,1.53] 1.50[0.85,2.65] 
Age Group (35~49 
vs 20~34) 
3.91[2.85,5.36]*** 1.33[0.97,1.83]* 4.22[2.62,6.80]*** 3.03[1.61,5.71]*** 
Gender (Male vs 
Female) 
1.38[1.02,1.88]** 1.81[1.36,2.41]*** 1.43[0.93,2.22] 1.70[0.92,3.13]* 
Race (nonWhite vs 
White) 
1.67[1.23,2.27]*** 1.52[1.14,2.03]*** - - 
Education (high 
school vs college or 
higher) 
1.12[0.83,1.51] 1.65[1.23,2.21]*** - - 
Household Income  1.24[0.81,1.88]   
<$25,000 
vs >$55,000 
1.88[1.06,3.35]**  2.48[1.36,4.54]*** 2.12[0.91,4.93]* 
$25,000~54,999 
vs >$55,000 
2.01[1.16,3.47]** 2.37[1.32,4.24]*** 2.29[0.98,5.38]* 
Smoking (Smoker 
vs nonsmoker) 
1.19[0.92,1.54] 1.63[1.22,2.19]*** - - 
Blood Pressure 
(High vs Normal) 
3.14[2.15,4.59]*** 1.67[1.27,2.20]*** - - 
BMI  1.48[1.08,2.03]**   
Overweight vs 
Normal  
2.30[1.44,3.66]***  - 2.45[1.09,5.52]** 
Obesity vs Normal 7.53[4.70,12.1]*** - 6.91[2.56,18.7]*** 
Blood Cholesterol 
Level 
 1.64[1.22,2.21]***   
Borderline high vs 
Desirable  
1.10[0.77,1.55]  - - 
High levels vs 
Desirable 
1.32[0.88,2.00] - - 
C reactive protein  1.53[1.14,2.07]***   
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High or Average vs 
Low or normal 
 
3.39[2.37,4.84]***  - 2.22[1.16,4.27]** 
Ferritin  2.11[1.38,3.24]***   
Normal levels vs 
Low levels 
1.70[1.01,2.86]**  - 2.10[0.84,5.23] 
High levels vs Low 
levels 
4.89[2.55,9.38]***  - 4.42[1.52,12.8]*** 
--: the predictor not included in the final multiple logistic regression model, * p < 0.10, ** p < 0.05,      
***p < 0.01  
a:  odds ratio (95% CI) btw T2DM by each risk factor only.  
b:  odds ratio (95% CI) btw T2DM and HSV-2 adjusted by each risk factor. 
c:  odds ratio (95% CI) btw T2DM and HSV-2 adjusted by demographic variables in one full model. 
d:  odds ratio (95% CI) btw T2DM and HSV-2 adjusted by demographic and clinical variables in one full 
model. 
 
 
Similarly, the correlation between T2DM and the number of infections with HSV-
1+HSV-2 was also examined (Table 8). The results of this analysis were consistent with 
those described in table 7. T2DM was associated with HSV-2, age, gender, race, 
household income, blood pressure, BMI, and ferritin. Unadjusted rates indicate that 
T2DM was 1.99 times more likely to occur among individuals who were seropositive for 
both HSV-1and HSV-2 than among individuals who acquired neither one (p = 0.0042). 
T2DM was 3.91 times more likely to occur among individuals aged 35~49 than among 
individuals aged 20~34 (p < 0.0001); 1.38 times more likely to occur among male than 
among female (p = 0.0392); 1.67 times more likely to occur among nonWhites than 
among Whites (p = 0.0013); 1.88 times more likely to occur among individuals with a 
household income below $25,000  than among individuals with a household income 
between $25,000 and $49,999 (p = 0.0309); 2.01 times more likely to occur among 
individuals with household income above $25,000 and less than $55,000 than among 
individuals with household income above $55,000 (p = 0.0133); 3.14 times more likely to 
occur among individuals with high blood pressure than among individuals with normal 
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blood pressure (p < 0.0001); 2.30 times more likely to occur among overweight 
individuals than among normal weight individuals (p = 0.0006) ; 7.53 times more likely 
to occur among obese individuals than among normal weight (p < 0.0001); 3.39 times 
more likely to occur among individuals with high to average level CRP than among 
individuals with low to normal CRP (p < 0.0001); 1.70 times more likely to occur among 
individuals with normal ferritin levels than among individuals with low levels 
(p=0.0461); and 4.89 more likely to occur among individuals with high levels of ferritin 
than among those with low levels (p < 0.0001) . However, T2DM was not associated 
with HSV-1, education, smoking, and blood cholesterol level. 
Adjusted rates determined that T2DM was 2.22 times more likely to occur among 
individuals who were seropositive for HSV-1and  HSV-2 than among individuals who 
were not (p = 0.0004) adjusted by gender (Column 2, Table 8); 1.69 (p = 0.0355) 
adjusted by race; 1.98 (p = 0.0042; adjusted by education; 1.96 (p = 0.0051) adjusted by 
smoking; 2.09 (p = 0.0021) adjusted by blood pressure; 1.71 (p = 0.0287) adjusted by 
BMI; 1.96 (p = 0.0057) adjusted by blood cholesterol; 1.82 (p = 0.0152) adjusted by 
CRP;  and 2.29 (p = 0.0246) if adjusted by ferritin. Having HSV-1and HSV-2 versus not 
having acquired any herpes virus was not significantly associated with T2DM when 
adjusted by age, gender, household income, BMI, CRP, or ferritin. However, all these 
confounders exhibited significance in this model (Column 3 and 4, Table 8). 
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Table 8 
 
Odds Ratios (95% Confidence Intervals) for T2DM Associated With Herpes Simplex 
Viruses (HSV-1and HSV-2) by Selected Covariates Among U.S. 20 to 49 Years Old 
Population, NHANES, 1999-2010  
 
 (1) Crudea (2) Adjustedb (3) Adjustedc (4) Adjustedd 
Herpes Type      
One type vs no 
herpes (HSV-1) 
1.20[0.78,1.85] 1.20[0.78,1.85] 1.02[0.57,1.83] 0.82[0.37,1.81] 
Two types vs no 
herpes (HSV-1 
and HSV-2) 
1.99[1.25,3.18]*** 1.99[1.25,3.18]*** 1.10[0.56,2.16] 1.50[0.62,3.67] 
Age Group 
(35~49 vs 20~34) 
3.91[2.85,5.36]*** 1.02[0.66,1.59] 4.17[2.53,6.88]*** 3.01[1.58,5.73]*** 
  1.42[0.88,2.32]   
Gender (Male vs 
Female) 
1.38[1.02,1.88]** 1.23[0.81,1.89] 1.44[0.94,2.20]* 1.69[0.94,3.03]* 
  2.22[1.44,3.43]***   
Race (nonWhite 
vs White) 
1.67[1.23,2.27]*** 1.10[0.70,1.71] - - 
  1.69[1.04,2.74]**   
Education (high 
school vs college 
or higher) 
1.12[0.83,1.51] 1.20[0.77,1.85] - - 
  1.98[1.24,3.16]***   
Household 
Income 
 1.23[0.68,2.22]   
  1.56[0.77,3.15]   
<$25,000 
vs >$55,000 
1.88[1.06,3.35]**  2.45[1.32,4.54]*** 2.09[0.90,4.84]* 
$25,000~54,999 
vs >$55,000 
2.01[1.16,3.47]** 2.34[1.31,4.18]*** 2.28[1.00,5.19]* 
Smoking 
(Smoker vs 
nonsmoker) 
1.19[0.92,1.54] 1.20[0.78,1.84]  - 
  1.96[1.23,3.12]***   
Blood Pressure 
(High vs Normal) 
3.14[2.15,4.59]*** 1.34[0.85,2.10] -  
  2.09[1.32,3.33]***   
BMI  1.10[0.70,1.71]   
  1.71[1.06,2.77]**   
Overweight vs 
Normal  
2.30[1.44,3.66]***  - 2.44[1.09,5.46]** 
Obesity vs 
Normal 
7.53[4.70,12.08]*** - 6.91[2.53,18.87]*** 
Blood 
Cholesterol Level 
 1.19[0.77,1.84]   
  1.96[1.22,3.15]***   
Borderline high 
vs Desirable  
1.10[0.77,1.55]  - - 
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High levels vs 
Desirable 
1.32[0.88,2.00] - - 
C reactive protein  1.17[0.75,1.83]   
  [1.82,1.13 2.93]**   
High or Average 
vs Low or 
Normal  
3.39[2.37,4.84]***  - 2.21[1.15,4.22]** 
Ferritin  1.06[0.54,2.11]   
  2.29[1.11,4.70]**   
Normal levels vs 
Low levels 
1.70[1.01,2.86]**  - 2.10[0.85,5.22] 
High levels vs 
Low levels 
4.89[2.55,9.38]***  - 4.52[1.54,13.25]*** 
--: the predictor not included in the final multiple logistic regression model, *p < 0.10, ** p < 0.05, 
***p<0.01  
a:  odds ratio (95% CI) btw T2DM and each risk factor only.  
b:  odds ratio (95% CI) btw T2DM and HSV adjusted by each risk factor. 
c:  odds ratio (95% CI) btw T2DM and HSV, demographic variables, and smoke in one full model. 
d:  odds ratio (95% CI) btw T2DM and HSV, demographic variables, smoke and all clinical variables in one 
full model. 
 
 
Relationship between CVD and HSV-2 and Burden of Infection 
 
The interaction between CVD and HSV-2 and selected demographic and clinical 
variables was also evaluated (Table 9). Similar to T2DM, results of the multiple logistic 
analysis (Column 1, Table 9 & 10) indicated that CVD was associated with individuals 
who were seropositive for HSV-2, age, education, household income, smoking, blood 
pressure, BMI, CRP, and ferritin. Specifically, CVD was 2.19 times more likely to occur 
among individuals who were HSV-2 positive than among individuals who did not (p = 
0.0002) and 2.65 (Column 1, Table 10) times more likely to occur among individuals 
who acquired both HSV-1and HSV-2 than among individuals who acquired neither one 
(p = 0.0013); 4.81 times as likely to occur among individuals aged 35~49 than among 
individuals aged 20~34 (p <0.0001); 1.62 times more likely to occur among individuals 
with high school education than among individuals with college or higher education       
(p = 0.0192);  2.24 times more likely to occur among individuals with household income 
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below $25,000  than among individuals with household income above $25,000 and less 
than $55,000 (p = 0.0040); 1.73 times more likely to occur among individuals with 
household income above $25,000 and less than $55,000 than among individuals with 
household income above $55,000 (p = 0.0609); 3.66 times more likely to occur among 
smoking individuals than among nonsmoking individuals (p < 0.0001);  2.43 times more 
likely to occur among individuals with high blood pressure than among individuals with 
normal blood pressure (p = 0.0017); 1.97 times more  likely to occur among overweight 
individuals than among normal weight individuals (p = 0.0185); 3.25 times more likely to 
occur among obese individuals than among normal weight (p < 0.0001); 1.89 times more 
likely to occur among individuals with high to average level CRP than among individuals 
with low to normal CRP (p = 0.0130);  2.97 times more likely to occur among individuals 
with high level ferritin than among individuals with low level ferritin (p = 0.0185). 
Nonetheless, CVD was not associated with HSV-1, CMV, gender, race, cholesterol level, 
or burden of infections. 
The odds ratios between CVD and HSV-2 adjusted by each of the demographic 
and clinical variables are shown (Column 2, Table 9 &10). CVD was found 1.73 
(p=0.0097) times more likely to occur among individuals who were seropositive for 
HSV-2 than among individuals who were not if adjusted by age (Column 2, Table 9); 
2.21(p = 0.0001) adjusted by gender; 2.32 (p = 0.0001) adjusted by race; 2.13(p=0.0003) 
adjusted by education; 1.91 (p = 0.0024) adjusted by smoking; 2.06 (p = 0.0011) adjusted 
by blood pressure; 2.07 (p = 0.0009) adjusted by BMI; 2.16  (p = 0.0003) adjusted by 
blood cholesterol; 2.12 (p = 0.0004) adjusted by CRP; and 2.07 (p = 0.0023) adjusted by 
81 
 
 
ferritin. Based on the 10% rule (Vittinghoff et al., 2012), it was observed that age, 
household income and smoking were negative confounders of HSV-2. To identify 
potential confounders between CVD and HSV-2, a stepwise regression analysis was also 
performed. CVD was not associated with HSV-2 when adjusted by age, household 
income; and smoking and BMI (Column 3, Table 9).Nevertheless, all the confounding 
variables were found significant at alpha=0.10, 0.05, or 0.01 (Column 4, Tables 9 & 10). 
Table 9 
 
Odds Ratios (95% Confidence Intervals) for CVD Associated With HSV-2 and Burden of 
Infection by Selected Covariates Among U.S. 20 to 49 Years Old Population, NHANES, 
1999-2010 
 (1) Crudea (2) Adjustedb (3) Adjustedc (4) Adjustedd 
HSV-2  (Yes vs No) 2.19[1.47,3.27]*** 2.19[1.47,3.27]*** 1.03[0.59,1.80] 1.08[0.59,1.95] 
BURDEN*  -  - 
1 vs 0 1.03[0.48,2.18]  - - 
2 vs 0 0.69[0.28,1.68] - - 
3 vs 0 1.62[0.72,3.66] -  
Age Group (35~49 vs 20~34) 4.81[3.04,7.63]*** 1.73[1.15,2.62]*** 5.19[2.59,10.37]*** 4.48[2.25,8.94]*** 
Gender (Male vs Female) 0.89[0.60,1.31] 2.21[1.50,3.25]*** - - 
Race (nonWhite vs White) 0.84[0.58,1.22] 2.32[1.53,3.52]*** - - 
Education (high school vs college 
or higher) 
1.62[1.08,2.42]** 2.13[1.42,3.18]*** - - 
Household Income  1.50[0.88,2.55]   
<$25,000 vs >$55,000 2.24[1.30,3.86]***  2.45[1.39,4.32]*** 2.34[1.33,4.10]*** 
$25,000~54,999 vs >$55,000 1.73[0.97,3.08]* 1.92[1.06,3.48]** 1.80[0.94,3.42]* 
Smoking (Smoker vs nonsmoker) 3.66[2.42,5.53]*** 1.91[1.26,2.87]*** 2.47[1.39,4.41]*** 2.44[1.40,4.27]*** 
Blood Pressure (High vs Normal) 2.43[1.41,4.20]*** 2.06[1.35,3.16]** - - 
BMI  2.07[1.36,3.15]***   
Overweight vs Normal  1.97[1.12,3.46]**  - 3.18[1.45,6.97]*** 
Obesity vs Normal 3.25[1.89,5.62]*** - 3.67[1.70,7.93]*** 
CMVIGG 1.04[0.60,1.79] - - - 
Blood Cholesterol Level  2.16[1.44,3.24]***   
Borderline high vs Desirable  1.07[0.69,1.66]  - - 
High levels vs Desirable 1.43[0.78,2.60] - - 
C reactive protein  2.12[1.41,3.18]***   
High or Average vs Low or Normal  1.89[1.12,3.20]**  - - 
Ferritin  2.07[1.30,3.27]**   
Normal vs Low  1.36[0.61,3.04]  - - 
High vs Low  2.97[1.21,7.34]** - - 
--: the predictor not included in the final multiple logistic regression model, *p < 0.10, ** p < 0.05, 
***p<0.01 a:  odds ratio (95% CI) btw CVD by each risk factor only.  
b:  odds ratio (95% CI) btw CVD and HSV-2 adjusted by each risk factor. 
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c:  odds ratio (95% CI) btw CVD and HSV-2, demographic variables in one full model. 
d:  odds ratio (95% CI) btw CVD and HSV-2, demographic variables, and clinical and biometric variables 
in one full model. 
*: number of herpes infections (HSV-1 or HSV-2, HSV-1 and HSV-2, and HSV-1 and HSV-2 and (CMV) 
 
Table 10 illustrates the odd ratio for CVD and HSV-1 and HSV-2 and selected 
markers. Study results indicated that CVD was 1.84 times more likely to occur among 
individuals who were seropositive to both, HSV-1 and HSV-2 than among individuals 
who were not  (p = 0.0524) if adjusted by age; 2.66 (p = 0.0006) adjusted  by gender; 
3.02 (p=0.0008) adjusted by race; 2.40 (p = 0.0051) adjusted by education; 2.20              
(p = 0.0094) adjusted by smoking; 2.72 (p = 0.0012) adjusted by blood pressure; 2.45        
(p =0.0062) adjusted by BMI; 2.60 (p = 0.0015) adjusted by blood cholesterol level; 2.54  
(p = 0.0020) adjusted by CRP; 2.63 (p = 0.0056) adjusted by ferritin. The predictive 
effects of multiple variables were also assessed with a stepwise regression (3rd and 4th 
columns, Table 10). Results were comparable with T2DM, indicating not significant 
association between CVD and having HSV-1 and HSV-2 if adjusted by age, household 
income and smoking; however, age, household income and smoking showed significance 
in all regression models.  
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Table 10 
 
Odds Ratios (95% Confidence Intervals) for CVD Associated With HSV-1 and HSV-2 and 
Selected Markers Among U.S. 20 to 49 Years Old Population, NHANES, 1999-2010 
(HSV) 
 
 (1) Crudea (2) Adjustedb (3) Adjustedc (4) Adjustedd 
Herpes Type     
One types vs No herpes (HSV-1) 1.35[0.81,2.24] 1.35[0.81,2.24] 0.67[0.35,1.30] 0.75[0.38,1.47] 
Two types vs No herpes (HSV-1 + 
HSV-2) 
2.65[1.48,4.73]*** 2.65[1.48,4.73]*** 0.79[0.35,1.77] 0.87[0.36,2.13] 
     
Age Group (35~49 vs 20~34) 4.81[3.04,7.63]*** 1.12[0.66,1.90] 5.51[2.61,11.65]*** 4.68[2.25,9.71]*** 
  1.84[0.99,3.39]*   
     
Gender (Male vs Female) 0.89[0.60,1.31] 1.35[0.82,2.23] - - 
  2.66[1.53,4.60]***   
     
Race (nonWhite vs White) 0.84[0.58,1.22] 1.44[0.86,2.42] - - 
  3.02[1.61,5.68]***   
     
Education (high school vs college 
or higher) 
1.62[1.08,2.42]** 1.27[0.75,2.15] - - 
  2.40[1.31,4.41]***   
     
Household Income  0.93[0.52,1.66]   
  1.50[0.74,3.04]   
<$25,000 vs >$55,000 2.24[1.30,3.86]***  2.53[1.47,4.36]*** 2.39[1.37,4.18]*** 
$25,000~54,999 vs >$55,000 1.73[0.97,3.08]* 1.97[1.10,3.54]** 1.83[0.97,3.46]* 
     
Smoking (Smoker vs Nonsmoker) 3.66[2.42,5.53]*** 1.25[0.75,2.09] 2.52[1.42,4.49]*** 2.47[1.42,4.31]*** 
  2.20[1.22,3.96]***   
Blood Pressure (High vs Normal) 2.43[1.41,4.20]*** 1.16[0.69,1.97] - - 
  2.72[1.50,4.95]***   
     
BMI  1.38[0.81,2.34]   
  2.45[1.30,4.62]***   
Overweight vs Normal  1.97[1.12,3.46]**  - 3.17[1.44,6.95]*** 
Obesity vs Normal 3.25[1.89,5.62]*** - 3.68[1.72,7.91]*** 
     
Blood Cholesterol Level  1.34[0.80,2.22]   
  2.60[1.45,4.64]***   
Borderline high vs Desirable  1.07[0.69,1.66]  - - 
High levels vs Desirable 1.43[0.78,2.60] - - 
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C reactive protein  1.33[0.80,2.21]   
  2.54[1.42,4.56]***   
High or Average vs Low or Normal  1.89[1.12,3.20]**  - - 
     
Ferritin  1.24[0.63,2.43]   
  2.63[1.34,5.18]***   
Normal levels vs Low levels 1.36[0.61,3.04]  - - 
High levels vs Low levels 2.97[1.21,7.34]**  - - 
--: the predictor not included in the final multiple logistic regression model, *p < 0.10, ** p < 0.05, ***p < 0.01  
a:  odds ratio (95% CI) btw CVD and each risk factor only.  
b:  odds ratio (95% CI) btw CVD and HSV adjusted by each risk factor. 
c:  odds ratio (95% CI) btw CVD and HSV, demographic variables, and smoke in one full model. 
d:  odds ratio (95% CI) btw CVD and HSV, demographic variables, smoke and all clinical variables in one full model. 
 
Summary  
The multivariate regression analyses accounting for sampling design effects and 
sampling weight indicated that both T2DM and CVD were significantly associated with 
HSV-2, but not associated with HSV-1, CMV or burden (multiple infections). Results 
indicated that T2DM and CVD were associated with demographic variables age, 
household income, blood pressure, BMI, CRP and ferritin; however, only T2DM was 
associated with gender and race while CVD was associated with education and smoking. 
Surprisingly, neither T2DM nor CVD was associated with blood cholesterol. Further 
examination revealed  that nonwhite men, aged 35-49, with household income ≤$55,000, 
with high blood pressure, overweight or obese, with average to high level of CRP, or high 
ferritin levels were more likely to increase the risk for developing T2DM. Similarly, 
older individuals aged 35-49, smoking individuals, or those individuals with a high 
school education background, a household income ≤$25,000 or between $25,000 and 
≤$55,000, high blood pressure, overweight or obese, with an average or high CRP level, 
or high ferritin levels were more likely to increase the risk for developing CVD.  
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Further examination revealed that gender, age, household income, BMI and 
ferritin were confounders of the association between T2DM and HSV-2 while age, 
household income and smoking were cofounders of the association between CVD and 
HSV-2. Based on the stepwise regression model, the final regression model for 
describing the relationship between T2DM and HSV-2 was determined after adjusting for 
the demographic and clinical variables, age, gender, household income, BMI, CRP and 
ferritin. No association between T2DM and HSV-2 was observed after factoring for all 
confounding variables. Similarly, no significant association was observed between CVD 
and HSV-2 after adjusting for age, household income, and BMI. A similar trend was 
observed between T2DM and CVD and seropositivity to both, HSV-1 and HSV-2. After 
controlling for all confounding factors, no significant association was observed between 
HSV-2 and T2DM or CVD and having both HSV-1and HSV-2. However, a significant 
association was observed between T2DM and CVD and high CRP and ferritin levels 
across all analyses. Discussion on these findings and their implication on social changed 
are further discussed in Chapter 5.  
 
 
 
 
 
 
 
86 
 
 
Chapter 5 
Discussion, Conclusion, and Implications for Social Change 
Introduction 
The global prevalence and incidence of HSV is of great public health significance 
(CDC, 2010; Smith & Robinson, 2002; Wald & Corey, 2007; Xu et al., 2006). The ability 
of HSV to readily adapt to its host (human or animal), reactivate during the lifetime of 
the host, and induce recurrent autoimmune and inflammatory responses is believed to 
increase an individual’s susceptibility to disease (Kampoli et al., 2011; Lloyd-Jones et al., 
2010; Lutsey et al., 2009; Pickup, 2004; van der Kleij et al., 2003). Despite the body of 
evidence implicating herpes and other viral and bacterial infections in the pathogenesis of 
T2DM and CVD, most studies have generated inconsistent results (Lutsey et al., 2009; 
Rupprecht et al., 2001; Sun et al., 2004) and this study is no exception. Outcomes from 
this study indicated no association and therefore do not support the hypothesis that HSV 
or multiple infections with HSV and CMV increase the risk of developing either T2DM 
or CVD. In contrast, findings from this study support the premise that pathogenic 
inflammation may be a secondary phenomenon and not directly associated with the 
disease (ASM, 2014). 
Discussion 
This study was based on the premise that infectious agents can increase chronic 
inflammation—a risk factor for several common chronic diseases, including T2DM and 
CVD. The relationship between human pathogenic HSVs and T2DM or CVD was 
examined to determine whether an association exists or if it is merely a secondary effect. 
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Based on data availability, the effect of two inflammatory markers, ferritin and CRP, on 
T2DM and CVD was studied. Established risk factors for both, T2DM and CVD, 
including hypertension, overweight or obese, and smoking status were also examined in 
the present study. Data collected by NHANES from 1999-2010 on individuals between 
the ages 20-49 was used to conduct this study.  
According to national trends, the risk of developing T2DM increases with age; is 
greater among Hispanics, African Americans, Native Americans and Asians; is greater 
among individuals who are obese or overweight, and have hypertension. (ADA, 2014; 
CDC, 2014; Geiss et al., 2014; Menke, Rust, Fradkin, Cheng, & Cowie, 2014; Paeratakul, 
Lovejoy, Ryan, & Bray, 2002). The prevalence of T2DM in this sample was consistent 
with the overall national trends by gender, age, race/ethnicity, hypertension, and body 
mass index. A significantly higher prevalence of T2DM was observed among males than 
females, which supports the new trend in gender distribution of T2DM due to differences 
in body fat, insulin resistance, sex hormones, and blood glucose levels (Faerch, Borch-
Johnsen, Vaag, Jorgensen, & Witte, 2010; Geer & Shen, 2009; Logue et al., 2011; 
Perreault et al., 2008; Sicree et al., 2008). Further, this study found no relation between 
smoking and T2DM, which is surprising given the fact that smoking is a well-established 
risk factor for T2DM. Nonetheless, a possible explanation for this finding is the decline 
of cigarette smoking among adults in the last decade, particularly among individual with 
diabetes (Fan et al., 2013).  
T2DM is known to increase the risk of CVD and similar risk factors have been 
associated with both diseases (Grundy, Pasternak, Greenland, Smith, & Fuster, 1999; 
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Laakso, 2008; Luscher et al., 2003). Consequently, similar results in the prevalence of 
CVD were expected. The prevalence of CVD in this sample was also consistent with U.S. 
trends by age, high blood pressure, smoking, and BMI, but not by gender or ethnicity 
(Hahn, Health, & Chang, 1998). Surprisingly, neither T2DM nor CVD was related to 
high cholesterol. It is possible that this study may have been limited to detect significant 
prevalence differences in cholesterol levels among study participants due to sample size, 
in addition to the multidimensional factors associated with T2DM and CVD (Dokken, 
2008; Kalofoutis et al, 2007).  
The prevalence of high CRP and ferritin levels in this study was also consistent 
with national estimates (Khera et al, 2005; Woloshin, & Schwartz, 2005). High CRP 
levels were observed among females, nonHispanic Blacks and Hispanics. Significantly 
higher CRP levels were, however, observed among nonHispanic Whites. It is possible 
that the analysis performed to assess race/ethnicity in this study may have been biased 
given that the majority of the study participants were nonHispanic Whites. Additionally, 
race and/or ethnicity in NHANES data is restricted to only a few classifications, 
including nonHispanic White, nonHispanic Black, Hispanics, and other racial groups, 
which limit the subgroup analyses in this study. Further, this study also found, although 
slightly, higher CRP levels among individuals aged 20-34 than in the older group. These 
unexpected and divergent results may be an indication of a new trend in the distribution 
of CRP in the U.S. since CVD has been risen among young people due to childhood 
obesity and diabetes (Freedman, Zuguo, Srinivasan, Berenson, & Dietz, 2007). Based on 
Freedman and associates (2007) findings, approximately 70% of obese youth between the 
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ages of 5-17 had at least one risk factor for CVD, including prediabetes and high blood 
pressure.  
Contrary to CRP, the prevalence of ferritin levels in this sample population was 
predominantly higher among males, nonHispanic Whites, and study participants aged 35-
49. Except for the factor race which limitations were previously discussed, these findings 
align with the overall distribution of serum ferritin reported by WHO (2014). Further 
analyses indicated that the prevalence of T2DM and CVD (age-adjusted) was 
significantly higher among individuals with the average to high CRP and high ferritin 
levels. These results support the use of CRP and ferritin levels as markers of chronic 
inflammatory disease and potential independent predictors of T2DM and CVD (Foroubi 
et al., 2007; Halcox et al., 2014; Watson et al., 2012). Whereas gender differences were 
observed with serum ferritin in this study, these results provide value to the use of serum 
ferritin in assessing the risk for T2DM and CVD.  
A decrease in the prevalence of HSV-1, HSV-2, and CMV over the last decade 
was observed in this study population, which also shows consistency with the national 
estimates (CDC, 2010a, 2010b; Smith et al., 2002; Staras et al., 2006; Xu et al., 2006). A 
similar tendency was observed among participants who had two or three herpes virus 
infection indicating a possible additive effect, particularly between HSV-1 and HSV-2, 
since the incidence of genital herpes with HSV-2 has been decreasing while potentially 
increasing with HSV-1 (Malkin, 2004). All three herpes virus infections were higher 
among females and individuals aged 35-49; however, the prevalence rates for HSV-2 
were twice as high. Significant racial differences were observed in the prevalence of 
90 
 
 
HSV-2 among nonHispanic Blacks whereas higher prevalence rates of HSV-1 were 
observed among Hispanics, followed by other racial populations and nonHispanic Blacks 
as documented in prior studies (Fanfair et al., 2013; Halford et al., 2004; Kriebs, 2008).  
Overall, results from unadjusted and adjusted analyses determined an association 
between T2DM and HSV-2 OR = 1.66 [1.23, 2.23], T2DM and both HSV-1 and HSV-2 
OR = 1.99 [1.25, 3.18], CVD and HSV-2 OR = 2.19 [1.47, 3.27] and CVD and both 
HSV-1 and HSV-2 OR = 2.65 65[1.48, 4.73]. Nevertheless, after controlling for all 
potential confounding variables in one full model, including smoking status, blood 
pressure, BMI, CRP, and serum ferritin, the associations were no longer significant. 
There was also no association between T2DM or CVD and HSV-1, CMV and burden of 
infection ≥1. These results support preceding evidence that no association exists between 
HSV and CMV and T2DM or CVD. However, all the covariates included in the final 
regression analyses showed a significant association with T2DM and CVD. These 
findings are consistent with the existing evidence that established risk factors such as 
hypertension, overweight or obese, and smoking status are associated with T2DM and 
CVD. 
Similar differing results have been reported in preceding studies investigating the 
association of multiple pathogens with chronic diseases. Lutsey and colleagues (2009) 
reported a high prevalence of diabetes among individuals with CMV OR = 1.73 [1.06, 
2.84], HSV-1 and HSV-2 OR = 2.73 [1.30, 5.75] and with more than 3 pathogens OR = 
1.68 [1.07, 2.64]; however, these associations were no longer significant after adjusting 
for selected demographic variables CMV OR = 1.02 [0.60, 1.72], HSV-1 and HSV-2    
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OR = 1.50 [0.68, 3.28], and ≥ 3 pathogens OR = 0.81 [0.48, 1.37]. Null results were also 
documented by Mendy and colleagues (2013) who conducted a study with the same 
NHANES data (1999-2010) and age group 20-49 to investigate the relationship between 
CVD and HSVs. No association was found between CVD and HSV-1 OR = 1.13 [95% 
CI = 0.79-1.62]. Whereas a positive association between HSV-2 and premature CVD   
OR = 1.56 [95% CI = 1.09-2.21] was reported in this study, this association could be 
debated as a weak association and may need further examination (Rosenthal, 1996). 
Other preceding work investigating the link between pathogens, socioeconomic position 
(SEP) and CVD reported no association between CVD and HSV-1, CVD and both HSV-
1 and HSV-2, or CVD and CMV after adjusting for SEP (Simanek, Dowd, & Aiello, 
2009). In contrast, CMV was identified as a possible mediator between socioeconomic 
and CVD and a co-factor in atherosclerosis (Simanek et al, 2009). 
Despite the null findings, the present study provides additional support to the 
existing literature that there is no association between T2DM or CVD and the studied 
herpes virus infections. It is possible, however, that these infectious agents are possible 
mediators in the inflammation process and co-factors in the early stage of the disease as 
reported in previous work (Bassols et al., 2009; Vlassara et al, 2002; Watts et al., 2008). 
Further, the null results of this study may be related to the study and analysis design. 
Although this study used a large sample size, subanalyses lowered the numbers and may 
have biased results. Further, a stepwise regression analysis was utilized since it allows for 
predictive variables to be added sequentially and altogether in a full model. A few 
controversial points, however, have been made with regards to stepwise regression, 
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including tests bias, type I error, distribution of F-statistic and over-simplifications of 
final models (Copas, 1983; Hurvich, & Tsai, 1990; Roecker, 1991; Wilkinson, & Dallal, 
1981). Nevertheless, all predictive variables in this study were manually selected; 
therefore, the issues mentioned above should not have influenced the results. Other 
potential factors that could have affected the results are variable manipulations in the 
analyses. The variable race/ethnicity, for instance, was recategorized from a multiple 
levels variable to a binary variable due to analysis constrains. Yet, given that most of this 
study population were nonHispanic Whites, aggregating all the underestimated 
populations should have in fact canceled out any effects. Additionally, this study looked 
at the distribution of all three herpes viruses (HSV-1, HSV-2 and CMV) by selected 
demographic variables, but not across all studied independent variables and covariates. It 
may be possible that the results may have been affected by some variable distribution; 
yet, the focus of the study was on two dependent variables, T2DM and CVD, and main 
covariates indicated normal distribution. Furthermore, the cutoff points for measuring 
certain biochemical parameters used in this study may have been different from those 
used in previous studies, which may have caused the differing results. 
Nevertheless, based on the evidence of this study, which associations were 
contributed to confounding, it is presumed that potential confounding factors for T2DM 
and CVD, other than demographic factors, were not adequately controlled in some of the 
previous studies. It is also assumed that other factors such as differences in settings, 
location, and study design may be related to the discrepancy between this study’s results 
and those preceding. Some of the limitations documented in prior works investigating the 
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role of infection in the prevalence of T2DM and CVD includes clinical populations, 
age/race-specific, and small sample sizes, which may preclude general population 
inferences (Lutsey et al., 2009; Paeratakul et al., 2002; Roberts et al., 2005a, 2005b; Sun 
et al., 2004). When compared to other cross-sectional studies, the present study does 
align for the most part with reported results (Lutsey et al., 2009; Mendy et al, 2013). 
Whereas causal factor cannot be assumed with the study design, and results were null, 
this study raises important questions to be addressed in future research.  
Limitations  
  This study used multiple years of NHANES data which requires different weights 
for analysis and is particularly important for variance estimation. This, however, resulted 
in a significant increase in the number of missing and a decrease in sample size across 
most of the studied variables. Further, the fact that CRP and ferritin levels are potentially 
linked to both diseases made it difficult to determine their true utility for each disease in 
this study. Additionally, data for these and other inflammatory markers were not 
consistently collected by NHANES throughout the 12 years of data collection period, 
making it difficult to make unbiased comparison analysis and inferences.  
Implications for Social Change 
Despite the null results, this study provides the medical community and the public 
health field with valuable information that can be translated into clinical practice. 
Although there is no definitive evidence that lowering CRP or serum ferritin levels can 
reduce the risk for diabetes or CVD, it has been documented that managing and 
controlling traditional risk factors, such as blood pressure, nutrition, exercise, and 
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smoking, often lead to lowering these inflammatory markers (Ridker, 2000; Ziegler, 
2005). Existing guidelines could be expanded for primary and secondary prevention of 
CVD and T2DM using CRP as a prognostic tool for CVD (Ballantyne et al., 2005; Blake 
et al., 2002; Davison et al., 2011; Khera et al., 2005; Ridker, 2000) and serum ferritin as a 
marker for T2DM and CVD even in healthy individuals (Forouhi et al, 2007; Olesnevich 
et al., 2012; Ossewaarde, 1998; Ponikowska et al., 2013). Although CPR testing for CVD 
risk assessment continues to be a subject of debate (Capuzzi & Freeman, 2007), using 
CRP as a marker for inflammatory disease is a widely accepted means for assessing 
metabolic syndrome risk and diabetes (Ballantyne et al., 2005; Blake et al., 2002; Ridker, 
2000). CPR has also been used to investigate the role of pathogen burden in relation to 
increased risk for atherosclerosis (Zhu et al., 1999).  
Implications for Future Research  
Findings from this study expand on the existing evidence that no association 
exists between herpes viruses (HSV-1, HSV-2, and CMV) and T2DM and CVD. The 
high prevalence of HSV-2 observed among individuals with T2DM and CVD, however, 
does raise the question whether infections agents have an etiologic role in disease 
development or if having a chronic disease increases the susceptibility to infection. 
Conflicting results underscore the need for more collaborative research across diseases 
like T2DM, CVD and HSV which are traditionally housed in separate silos for research 
and funding. Although no association was found in this study; certainly, conflicting 
growing evidence investigating the relation between infectious agents, particularly 
lifelong viruses, and chronic inflammatory diseases calls for causality research. 
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Longitudinal studies are particularly useful in detecting changes in a population over 
time, and the best method for thoroughly explore whether an association really exists 
between pathogens and chronic diseases or if it is merely an epiphenomenon. 
Understanding this relationship is imperative for developing preventive measures and 
treatment for T2DM and CVD. Further, the effect of the studied inflammatory markers 
(CRP and serum ferritin) as potential predictors for T2DM and CVD and mediators in the 
activation of inflammation still is unclear (Laakso, 2008; Vlassara et al., 2002; Watson et 
al., 2012; Watts et al., 2008). Further investigation is needed to advance understanding of 
the interrelationship between pathogenic agents, inflammation and chronic diseases. Last, 
high-risk groups often predisposed to chronic disease-related complications and 
susceptible to infections should be closed examined in future studies. 
Conclusion 
This study is the first to investigate the association between HSV and two 
multifactorial chronic diseases for which the primary etiology is unknown, T2DM and 
CVD. The present work also examined the relationship between two inflammatory 
markers (CRP and serum ferritin) and T2DM and CVD. Twelve years of cross-sectional 
data were used to generate a representative and acceptable sample size for this study. 
Results from this national representative sample indicated that being infected with HSVs, 
CMV, or with two or three herpes viruses does not increase the risk for developing 
T2DM or CVD. These findings suggest that infection may be a secondary phenomenon 
and is not directly associated with disease. However, considering the well-established 
connection between infection-induced autoimmune inflammatory response and disease, it 
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is presumed that perhaps pathogens may function as mediators or co-factors in the 
inflammatory response process, but not directly involved in the etiology of the disease. 
While causal studies may provide more precise information and better opportunities to 
assess, diagnose, and treat T2DM and CVD, the complexity of these two top leading 
causes of death in U.S. leads to the question if developing and implementing more 
effective prevention measures would be the best approach to address these two common 
chronic diseases.  
Despite this study’s marginal findings on infection and chronic disease, additional 
results from this study showed an association between inflammatory markers and T2DM 
and CVD. These results suggest that individuals with high levels of CRP or serum ferritin 
may be at higher risk of developing T2DM or CVD; these findings are of great 
significance mainly because the potential role that inflammatory markers may play in 
chronic inflammation and disease. Inflammatory markers and other biomarkers have been 
used for generations by scientists as disease status indicators; however, their reliability 
and validity as predictive tools for inflammatory diseases are still in debate. Whereas 
sensitivity and specificity measurements of biomarkers may be needed for determining 
progression and severity of a disease, the application of biomarkers should be included in 
routine screening tests to assist in disease prediction, diagnosis, management, and 
treatment.  
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